CAR T Cell Therapy Market

CAR T Cell Therapy Market (4th Edition) by Target Indications, Target Antigens (CD19, BCMA, CD19 / CD22, EGFR, NY-ESO-1 and Others), Key Players and Key Geographies: Industry Trends and Global Forecasts, 2022-2035

Lowest Price Guaranteed From USD 4,799
Published
October 2022
Pages
640
View Count
22908
Buy Now

Example Insights

Please refer below for insights

Report Description

CAR T Cell Therapy Market Overview

Global CAR T cell therapy market size is poised to reach USD 25 billion by 2035, growing at a CAGR of 20% from 2022 to 2035. Cancer is one of the leading cause of deaths, globally. In fact, as per the World Health Organization (WHO), 10 million cancer related deaths were reported in 2020. Further, it is estimated that, by the end of 2040, 27.5 million new cases will be added to the global cancer burden, exerting tremendous physical, emotional and financial strain on affected individuals, their families, communities as well as the national health systems. Even though a number of treatment options are available to control disease progression and keep malignant cells from spreading throughout the body, lasting remission is still difficult to achieve. Amidst the active initiatives undertaken to develop more targeted anti-cancer therapies, CAR T cell therapies have emerged as a promising option, given their ability to eradicate tumor cells from the body with minimal treatment-related side effects. Further, CAR-T immunotherapies, a relatively recent addition to the gamut of anticancer interventions, have demonstrated significant promise. Overall, this highly specific and promising form of cell therapy, which harnesses the versatile effector machinery of the human immune system, has revolutionized cancer treatment, globally. Given the consistent increase in number of cell therapies being developed and launched, this upcoming CAR T-cell therapy market is on its way to becoming one of the highest valued markets within the biopharmaceutical industry.

Key Market Insights

The CAR T Cell Therapy Market (4th Edition) by Key Drugs (Axicabtagene Ciloleucel, Tisagenlecleucel, Brexucabtagene Autoleucel, Ciltacabtagene Autoleucel, Lisocabtagene Maraleucel, Others), Target Indications (Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Hodgkin Lymphoma, Acute Myeloid Leukemia, Ovarian Cancer, Generalized Myasthenia Gravis And Renal Cell Carcinoma), Target Antigens (CD19, BCMA, CD19 / CD22, EGFR, NY-ESO-1 and Others), Key Players and Key Geographies (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World) – Global Forecast 2022-2035 report features an extensive study of the current market size and the future potential of CAR-T therapies. The report highlights the efforts of both industry players and academic organizations in this rapidly evolving segment of the biopharmaceutical industry. Amongst other elements, the market report answers several key questions related to the market.

Pipeline Analysis: 600+ CAR T Cell Therapy Programs in Clinical Trials

At present, of the seven approved CAR T cell therapies, six have been approved for several hematological malignancies in the US; these are Tisagenlecleucel-T (KYMRIAH®), Axicabtagene ciloleucel (YESCARTA®), Brexucabtagene Autoleucel (TECARTUS™), Lisocabtagene maraleucel (Breyanzi®), Idecabtagene Vicleucel (Abecma™) and Ciltacabtagene Autoleucel (CARVYKTI™). With 679 therapy programs in the clinical phases of development, CAR-T cell therapies have already established a strong foothold in the overall pharmaceutical industry. In addition, there are 289 CAR-T cell therapy programs in the preclinical stages of development that are likely to emerge as potential therapy candidates in the long term. The currently approved CAR-T therapies target the CD19 receptor and BCMA. However, CAR-T companies are developing therapies against several other novel targets that have been analyzed in this report. The expected launch of several promising leads over the forecast period, will drive the market growth.

CAR T Companies Analysis: Collaborations, Funding, Patents and More

170+ CAR T cell therapy companies are engaged in the development of over 970 early and late-stage CAR-T therapies, worldwide. More than 260 collaborations have been inked between several industry / academic stakeholders in order to advance the development of various pipeline candidates. To fund CAR-T cell therapy development, capital investments worth more than USD 24 billion have been made by various private and public sector investors, in the last few years. Additionally, over 6,500 patents related to CAR-T cell therapy have been recently filed / granted, demonstrating the continued innovation in this market. Driven by the ongoing pace of innovation in this field, sufficient financial support from investors and encouraging clinical trial results, the CAR T-cell therapy market size is likely to witness significant growth during the forecast period.

Target Indication Analysis: Acute Lymphoblastic Leukemia, B-Cell Lymphoma and Multiple Myeloma to Drive CAR T Cell Therapy Market Growth

According to the cancer data published by World Cancer Research Fund International, there were 474,519 new cases of leukemia, 176,404 new cases of multiple myeloma and 627,439 new cases of lymphoma worldwide in 2020. Many of the approved and clinical stage CAR T cell therapies target these hematological indications. Rising incidence and prevalence of cancer, as well as an increase in the relapse / remission rates will drive the adoption of CAR T cell therapies, driving the market growth. The developers of Idecabtagene Vicleucel (BMS) and Ciltacabtagene Autoleucel (Janssen and Legend Biotech) have published positive results from phase III trials for the treatment of multiple myeloma as earlier line of treatment compared to the currently approved status as fifth line therapies. Such developments will expand the potential market size for CAR-T therapies.

Regional Analysis: North America Holds the Largest Share of the Current CAR T Cell Therapy Market

On the basis of region, North America held 54% market share in terms of revenues generated through sales of approved CAR T cell therapies. This is likely to change during the forecast period, as Europe is projected to hold more than 37% share of the global market size. Although the process of approval of CAR-T therapies is accelerated through various grants, the high prices of treatment options continue to be one of the key challenges associated with CAR T cell therapy adoption. In the UK, Yescarta and Kymriah have been to date provided through National Health Services’s (NHS) Cancer Drugs Fund. However, this situation is likely to change as National Institute for Health and Care Excellence (NICE) is working on gathering evidence on cost-effectiveness of Yescarta. If approved, Axicabtagene Ciloleucel will become the first CAR T cell therapy to be provided to the patients through NHS. The European market will continue to grow at a healthy CAGR during the forecast period of this market report.

Market Forces Analysis: Therapy Price and Manufacturing Challenges Likely to Slow Down the CAR T Therapy Market Growth

Manufacturing biologics and cell therapies is considerably complex, as compared to small molecule drugs. The high manufacturing cost also contributes to high price of the therapy, essentially leading to limited adoption in case of unavailability of reimbursement. In 2021, BMS faced manufacturing bottleneck for its CAR-T idecabtagene vicleucel (ABECMA®), driven by shortage of viral vectors in addition to other reasons. In 2022, Janseen and Legend Biotech rolled out their CAR-T ciltacabtagene autoleucel (CARVYKTI ®) in a phased manner in the US instead of a nationwide launch owing to manufacturing limitations.

These challenges may be temporary as the market matures and is supported by the cell therapy contract manufacturers.

Recent Developments in CAR T Therapy Market

Several recent developments have taken place in the field of CAR T cell therapy. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.

In August 2023, the US FDA granted orphan drug designation (ODD) to NXC-201 (Nexcella), a next generation chimeric antigen receptor (CAR) T-cell therapy, for the treatment of patients suffering from multiple myeloma.
In August 2023, Invectys announced that FDA granted a Fast Track Designation to the chimeric antigen receptor (CAR) T-cell therapy, IVS-3001, which is used for the treatment of patients suffering from renal cell carcinoma.
In August 2023, GenScript Biotech entered into a strategic agreement with T-MAXIMUM Biotech with an aim to develop CAR T cell therapy by using GenScript's CRISPR nucleic acid reagents

Scope of the Report

Report Attribute	Details
Forecast Period	2022 – 2035
Market Size 2035	$25 billion
CAGR	20%
Base Year	2021
Target Indications	Non-Hodgkin's Lymphoma, Multiple Myeloma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Hodgkin's Lymphoma, Acute Myeloid Leukemia, Ovarian Cancer, Generalized Myasthenia Gravis, Renal Cell Carcinoma
Target Antigens	CD19, BCMA, CD19/CD22, Others
Key Players	Bristol Myers Squibb, Gilead Sciences, Novartis, Autolus, Janssen, JW Therapeutics, Beijing Immunochina Medical Science & Technology, Bioray Laboratories
Key Geographies	North America, Europe, Asia-Pacific, Middle East and North Africa, Latin America, Rest of the World

The market research report features an extensive study of the current market size and the future potential of CAR-T therapies. The report highlights the efforts of both industry players and academic organizations in this rapidly evolving segment of the biopharmaceutical industry. Amongst other elements, the report features the following:

A detailed assessment of the current market landscape of CAR-T therapies with respect to type of developer (industry and non-industry), phase of development (approved, phase III, phase II / III, phase II, phase I / II, phase I, clinical (phase unknown), preclinical), therapeutic area (oncological disorders, non-oncological disorders and undisclosed), key target indication (acute lymphoblastic leukemia, B-cell lymphoma, multiple myeloma, non-Hodgkin lymphoma, acute myeloid leukemia, hepatocellular carcinoma, diffuse large B-cell lymphoma, pancreatic cancer, gastric cancer, lung cancer, mantle cell lymphoma, ovarian cancer, breast cancer and follicular lymphoma), key target antigen (CD19, BCMA, CD19 / CD22, GPC3, NY-ESO-1 and others), source of T-cells (autologous and allogeneic), route of administration (intravenous, intratumoral, intraperitoneal, intrapleural, intracranial and others), dose frequency (single dose, multiple doses and split doses), patient segment (children, adults and seniors) and type of therapy (monotherapy and combination therapy). Additionally, it highlights the most active industry and non-industry players (in terms of number of pipeline candidates) engaged in the development of CAR T cell therapy. Further, chapter also includes developer landscape analysis based on some relevant parameters, including year of establishment, company size (small, mid-sized and large) and location of headquarters (North America, Europe and Asia Pacific).
An analysis of key insights derived from the study featuring a competitive analysis, highlighting the popular target antigens related to hematological malignancies and solid tumors. Additionally, it includes CAR construct analysis of clinical-stage CAR-T therapies based on the generation of CAR (first generation, second generation, third generation and fourth generation), type of binding domain (murine, humanized, fully human and rabbit derived), type of virus used (lentivirus and retrovirus), type of gene transfer method used (transduction and transfection) and type of co-stimulatory domain used.
A detailed analysis of completed, ongoing and planned clinical studies related to CAR T cell therapies, based on several relevant parameters, such as trial registration year, enrolled patient population, trial recruitment status, trial phase, target patient segment, type of sponsor / collaborator, most active players and regional distribution of trials.
An insightful analysis highlighting the key opinion leaders (KOLs) in this domain featuring an analysis of the various principal investigators of clinical trials related to CAR-T therapies, considering them to be KOLs, who are actively involved in R&D of CAR T cell therapies. In addition, the chapter presents an analysis, comparing the relative expertise of KOLs based on a proprietary scoring criterion and that of a third party.
Elaborate profiles of marketed and mid- to late-stage clinical products (phase I/II or above); each profile features an overview of the therapy, its mechanism of action, dosage information, details on the cost and sales information (wherever available), clinical development plan, and key clinical trial results.
An analysis of various type of partnership that have been inked between several stakeholders in the domain of CAR-T cell therapies, covering various type of partnership such as, R&D agreements, license agreements (specific to technology platforms and product candidates), product development and commercialization agreements, manufacturing agreements, clinical trial collaborations, product supply management agreements, joint ventures and others.
An analysis of the investments that have been made into CAR-T companies that have proprietary CAR-T therapies / technologies, including seed financing, venture capital financing, capital raised from IPOs and subsequent offerings, grants and debt financing.
An in-depth analysis of patents related to CAR T cell therapies, filed / granted till 2022, based on several relevant parameters, such as type of patent (granted patents, patent applications and others), publication year, geographical distribution, Cooperative Patent Classification (CPC) symbols, emerging focus areas, type of applicant, leading players (on the basis of number of patents) and patent benchmarking. In addition, it features a patent valuation analysis which evaluates the qualitative and quantitative aspects of the patents.
A case study on manufacturing cell therapy products, highlighting the key challenges, and a detailed list of contract service providers and in-house manufacturers involved in this space.
An elaborate discussion on various factors that form the basis for the pricing of cell-based therapies. It features different models / approaches that a pharmaceutical company may choose to adopt to decide the price of a CAR T therapy that is likely to be marketed in the coming years.
A review of the key promotional strategies being adopted by the developers of the approved CAR T cell therapies, namely Kymriah®, Yescarta®, Tecartus™, Breyanzi®, Abecma™, Carvykti™ and TCR-based therapies (Kimmtrak®).
Elaborate profiles of the several leading players in the domain of CAR T cell therapies. Each company profile includes an overview of the developer and brief description of the product portfolio specific to CAR-T therapies, technology portfolio (if available), recent developments related to T-cell immunotherapies and manufacturing capabilities of the companies. Additionally, we have provided details of the strategic / venture capital investments made in these companies.

One of the key objectives of the report was to estimate the CAR T therapy market size and identify potential growth opportunities for CAR-T cell therapies over the coming decade. Based on several parameters, such as target consumer segments, region specific adoption rates and expected prices of such products, we have developed informed estimates of the likely evolution of the market over the period 2022-2035. The report also includes likely sales forecasts of CAR T cell therapies that are already marketed or in the late stages of development. Additionally, it features market size projections for the overall CAR T-cell therapy market, wherein opportunity has been segmented across [A] key drugs (Axicabtagene Ciloleucel, Tisagenlecleucel, Brexucabtagene Autoleucel, Ciltacabtagene Autoleucel, Lisocabtagene Maraleucel, Others), [B] target indications (non-hodgkin lymphoma, multiple myeloma, acute lymphoblastic leukemia, chronic lymphocytic leukemia, hodgkin lymphoma, acute myeloid leukemia, ovarian cancer, generalized myasthenia gravis and renal cell carcinoma), [C] target antigens (CD19, BCMA, CD19 / CD22 and others), Key Players and [D] key geographies (North America (US and Canada), Europe (UK, Germany, France, Italy, Spain and rest of EU), Asia Pacific (China, Japan, Australia), Latin America, Latin America, Middle East and North Africa and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios namely the conservative, base and optimistic scenarios, which represent different tracks of the industry’s evolution.

The opinions and insights presented in this study were influenced by discussions conducted with several stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals:

Troels Jordansen (Chief Executive Officer, Glycostem Therapeutics)
Wei (William) Cao (Chief Executive Officer, Gracell Biotechnologies)
Miguel Forte (Chief Operating Officer, TxCell)
Adrian Bot (Vice President, Scientific Affairs, Kite Pharma)
Vincent Brichard (Vice President, Immuno-Oncology, Celyad)
Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing)
Aino Kalervo (Former Competitive Intelligence Manager, Strategy & Business Development, Theravectys)
Xian-Bao Zhan (Professor of Medicine and Director, Department of Oncology, Changhai Hospital)
Enkhtsetseg Purev (Assistant Professor of Medicine, University of Colorado)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market report are in USD, unless otherwise specified.

Frequently Asked Questions

Question 1: What is CAR T cell therapy?

Answer: CAR-T therapy is defined as a genetically enhanced T-cell therapy or adoptive T-cell therapy that harnesses the innate potential of immune cells, specifically T-cells, to potentially combat a myriad of diseases.

Question 2: How many CAR-T therapies are on the market?

Answer: There are currently seven approved CAR-T therapies, of which six have received FDA approval.

Question 3: What is the market size for CAR T cell therapy?

Answer: The global CAR T cell therapy market size is poised to reach USD 25 billion by 2035. These represent the potential revenues generated by the currently marketed CAR-T therapies and the drugs that are likely to receive approval during the forecast period.

Question 4: What is the global CAR T cell therapy market growth?

Answer: Global CAR T cell therapy market is expected to grow at a CAGR of 23% from 2022 to 2035.

Question 5: Who are the largest CAR T cell therapy companies?

Answer: Currently, close to 55% of the CAR T cell therapy market share is captured by Novartis and Gilead Sciences as both the companies have one and two approved CAR-T cell therapies, respectively, in the market.

Question 6: How many clinical trials are running for CAR-T therapies?

Answer: As of March 2022, there were more than 600 active trials for CAR T-cell therapies. Of these active trials, more than 50% trials are being conducted in Asia-Pacific.

Question 7: What kind of partnership models are commonly adopted by players in CAR-T industry?

Answer: 50% agreements signed in the domain of CAR T-cell therapy were related to licensing and R&D agreements. In addition, more than 30 agreements were inked for the product development and commercialization of CAR-T therapies.

Question 8: How much funding has been raised in the CAR T-cell therapy market?

Answer: In the year 2021, CAR T-cell therapy developers raised USD 4 billion. In terms of type of funding, a number of players developing CAR T cell therapy have managed to secure significant capital amounts through secondary offerings.

Question 9: How is the intellectual property landscape for global CAR T-cell therapy likely to evolve in the foreseen future?

Answer: A number of patents have been filed by several companies / organizations in order to protect novel intellectual property generated within this field, with majority of the patents (35%) filed / granted in Asia-Pacific. The trend is likely to continue due to extensive involvement of academic institutes based in China in the CAR T cell therapy product and technology development.

Question 10: Who are the key CAR T cell therapy CMOs?

Answer: Some of the key T-cell therapy CMOs include (in alphabetical order) BioNTech, CELLforCure, Cell and Gene Therapy Catapult, Cellular Biomedicine Group, Cellular Therapeutics, Lonza, MaSTherCell, Oxford BioMedica and WuXi AppTec.

Question 11: What are the key promotional strategies used by CAR T cell therapy companies having marketed products?

Answer: Promotional messages for all the therapies are primarily focused on the treatment process, dosing and route of administration. Detailed analysis for promotional strategies for the marketed CAR-T therapies is available in the report.

Question 12: What is the outlook for CAR T therapy?

Answer: CAR T therapies are promising class of immunotherapy, that have provided late line of treatment option for some of the leading hematological cancers. The pipeline is wide, with currently approved CAR-Ts also being tested for second-line of treatment. These approvals will lead the market growth in the near future, with long-term CAR T cell therapy market growth driven by new approvals and improved access of these therapies across the world.

Contents

1. PREFACE
1.1. Chapter Overview
1.2. Market Segmentations
1.3. Research Methodology
1.4. Key Questions Answered
1.5. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Pillars of Cancer Therapy
3.3. Overview of Immunotherapies
3.4. Fundamentals of Cancer Immunotherapy
3.5. Classification of Cancer Immunotherapy
3.5.1. By Mechanism of Action
3.5.1.1. Active Immunotherapy
3.5.1.2. Passive Immunotherapy
3.5.2. By Type of Target
3.5.3. By Approach
3.5.3.1. Activation and Suppression Immunotherapy

3.5.4. By Product Class
3.5.4.1. Monoclonal Antibodies
3.5.4.2. Bispecific Antibodies
3.5.4.3. Cytokines
3.5.4.4. Oncolytic Virus Therapy
3.5.4.5. Therapeutic Cancer Vaccines
3.5.4.6. Cell-based Therapies

3.6. T-Cell Immunotherapies
3.6.1. Historical Evolution
3.6.2. Key Considerations for Developing T-Cell Immunotherapies
3.6.3. Strategies Employed for the Redirection of T-Cells
3.6.4. Manufacturing of Engineered T-Cells
3.6.5. T-Cell Transduction and Transfection Methods
3.6.5.1. Retroviral Vectors
3.6.5.2. Lentiviral Vectors
3.6.5.3. Non-viral Transfection Methods

3.7. Chimeric Antigen Receptor T-Cell (CAR-T) Therapy
3.7.1. Development History
3.7.2. Anatomical Layout of CAR
3.7.2.1. Ectodomain
3.7.2.2. Transmembrane (TM) Domain
3.7.2.3. Endodomain
3.7.3. Development of CAR-T Cells
3.7.4. Universal CAR-T Cells
3.7.5. Route of Administration
3.7.6. Case Study on CD19 CAR-T Cell Therapies
3.7.6.1. Other Important Biological Targets for CAR Development

3.7.7. Challenges Associated with CAR-T Cell Therapies
3.7.7.1. Competitive Risks
3.7.7.2. Clinical Risks
3.7.7.3. Regulatory Risks
3.7.7.4. Commercial Risks
3.8. Concluding Remarks

4. CAR T CELL THERAPY: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. CAR T Cell Therapy: Overall Market Landscape
4.2.1. Analysis by Type of Developer
4.2.2. Analysis by Phase of Development
4.2.3. Analysis by Therapeutic Area
4.2.4. Analysis by Phase of Development and Therapeutic Area
4.2.5. Analysis by Key Target Indication
4.2.6. Analysis by Key Target Antigen
4.2.7. Analysis by Source of T-Cells
4.2.8. Analysis by Phase of Development and Source of T-Cells
4.2.9. Analysis by Route of Administration
4.2.10. Analysis by Dosing Frequency
4.2.11. Analysis by Target Patient Segment
4.2.12. Analysis by Type of Therapy
4.2.13. Most Active Industry Players: Analysis by Number of CAR T-Cell Therapies
4.2.14. Most Active Non-Industry Players: Analysis by Number of CAR T-Cell Therapies

4.3. CAR T Cell Therapy: Overall Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters

5. KEY INSIGHTS
5.1. Chapter Overview
5.2. CAR T-Cell Therapies: Competitive Analysis of Popular Target Antigens
5.2.1. Popular Targets Related to Hematological Malignancies
5.2.2. Popular Targets Related to Solid Tumors

5.3. T-Cell Immunotherapies: CAR Construct Analysis
5.3.1. Analysis by Generation of CAR
5.3.2. Analysis by Type of scFv Antibody
5.3.3. Analysis by Type of Virus Used
5.3.4. Analysis by Type of Gene Transfer Method Used
5.3.5. Analysis by Type of Co-Stimulatory Domain

6. CLINICAL TRIAL ANALYSIS
6.1. Chapter Overview
6.2. Scope and Methodology
6.3. CAR T-Cell Therapies: Clinical Trial Analysis
6.3.1. Analysis of Trials by Trial Registration Year
6.3.2. Analysis of Enrolled Patient Population by Trial Registration Year
6.3.3. Analysis by Trial Status
6.3.4. Analysis by Trial Registration Year and Trial Status
6.3.5. Analysis by Trial Phase
6.3.6. Analysis of Enrolled Patient Population by Trial Phase
6.3.7. Analysis by Target Patient Segment
6.3.8. Analysis by Type of Sponsor / Collaborator
6.3.9. Analysis by Study Design
6.3.10. Most Active Industry Players: Analysis by Number of Registered Trials
6.3.11. Most Active Non-Industry Players: Analysis by Number of Registered Trials
6.3.12. Analysis by Key Focus Areas
6.3.13. Analysis of Trials by Geography
6.3.14. Analysis of Enrolled Patient Population by Geography

7. KEY OPINION LEADERS
7.1. Chapter Overview
7.2. Assumptions and Key Parameters
7.3. Methodology
7.4. CAR-T Cell Therapies: Key Opinion Leaders
7.4.1. Analysis by Type of Organization
7.4.2. Analysis by Affiliated Organization
7.4.3. Analysis by Qualification
7.4.4. Analysis by Geographical Location of KOLs
7.4.5. KOL Activeness versus KOL Strength
7.4.6. Most Prominent KOLs: Analysis by RA score
7.4.7. Most Prominent KOLs: Comparison of RA Score and Third-Party Score

8. CAR-T CELL THERAPY PROFILES
8.1. Chapter Overview
8.2. Kymriah / Tisagenlecleucel / CTL019 (Novartis)
8.2.1. Therapy Overview
8.2.2. Clinical Trial Information
8.2.3. Clinical Trial Endpoints
8.2.4. Clinical Trial Results
8.2.5. Estimated Sales Revenues

8.3. Yescarta / Axiscabtagene Ciloleucel / KTE-C19 (Gilead Sciences)
8.3.1. Therapy Overview
8.3.2. Clinical Trial Information
8.3.3. Clinical Trial Endpoints
8.3.4. Clinical Trial Results
8.3.5. Estimated Sales Revenues

8.4. Tecartus / Brexucabtagene Autoleucel (Gilead Sciences)
8.4.1. Therapy Overview
8.4.2. Clinical Trial Information
8.4.3. Clinical Trial Endpoints
8.4.4. Clinical Trial Results
8.4.5. Estimated Sales Revenues

8.5. Breyanzi / Lisocabtagene Maraleucel / JCAR017 (Bristol Myers Squibb)
8.5.1. Therapy Overview
8.5.2. Clinical Trial Information
8.5.3. Clinical Trial Endpoints
8.5.4. Clinical Trial Results
8.5.5. Estimated Sales Revenues

8.6. Abecma / BB2121 / Idecabtagene Vicleucel (Bristol Myers Squibb)
8.6.1. Therapy Overview
8.6.2. Clinical Trial Information
8.6.3. Clinical Trial Endpoints
8.6.4. Clinical Trial Results
8.6.5. Estimated Sales Revenues

8.7. Carvykti / Ciltacabtagene Autoleucel / LCAR-B38M CAR-T / JNJ-68284528 (Janssen)
8.7.1. Therapy Overview
8.7.2. Clinical Trial Information
8.7.3. Clinical Trial Endpoints
8.7.4. Clinical Trial Results
8.7.5. Estimated Sales Revenues

8.8. Carteyva / Relmacabtagene Autoleucel / JWCAR029 (JW Therapeutics)
8.8.1. Therapy Overview
8.8.2. Clinical Trial Information
8.8.3. Clinical Trial Endpoints
8.8.4. Clinical Trial Results
8.8.5. Estimated Sales Revenues

8.9. TBI-1501 / CD19 CAR-T Cell Therapy (Takara Bio)
8.9.1. Therapy Overview
8.9.2. Clinical Trial Information
8.9.3. Clinical Trial Endpoints

8.10. AUTO1 / Obecabtagene Autoleucel / obe-cel (Autolus)
8.10.1. Therapy Overview
8.10.2. Clinical Trial Information
8.10.3. Clinical Trial Endpoints
8.10.4. Clinical Trial Results
8.10.5. Estimated Sales Revenues

8.11. AUTO3 / CD19/22 CAR-T (Autolus)
8.11.1. Therapy Overview
8.11.2. Clinical Trial Information
8.11.3. Clinical Trial Endpoints
8.11.4. Clinical Trial Results
8.11.5. Estimated Sales Revenues

9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. CAR-T Cell Therapies: Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Year of Partnership and Type of Partnership
9.3.4. Analysis by Type of Partner
9.3.5. Most Popular Products: Analysis by Number of Partnerships
9.3.6. Most Active Industry Players: Analysis by Number of Partnerships
9.3.7. Most Active Non-Industry Players: Analysis by Number of Partnerships

9.3.8. Analysis by Geography
9.3.8.1. Intercontinental and Intracontinental Deals
9.3.8.2. International and Local Deals

10. FUNDING AND INVESTMENT ANALYSIS
10.1. Chapter Overview
10.2. Types of Funding
10.3. CAR-T Cell Therapies: Funding and Investment Analysis
10.3.1. Analysis of Instances by Year
10.3.2. Analysis of Amount Invested by Year
10.3.3. Analysis by Type of Funding
10.3.4. Analysis by Type of Investor
10.3.5. Most Active Players: Analysis by Number of Instances
10.3.6. Most Active Investors: Analysis by Amount Invested
10.3.7. Analysis of Amount Invested by Geography
10.3.8. Most Active Investors: Analysis by Number of Funding Instances

11. PATENT ANALYSIS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. CAR-T Cell Therapies: Patent Analysis
11.3.1. Analysis by Patent Publication Year
11.3.2. Analysis by Patent Application Year
11.3.3. Analysis by Geography
11.3.4. Analysis by Type of Player
11.3.5. Analysis by CPC Symbols
11.3.6. Analysis by Key Focus Area
11.3.7. Leading Players: Analysis by Number of Patents
11.3.8. CAR T-Cell Therapies: Patent Benchmarking
11.3.9. Analysis By Patent Characteristics
11.3.10. CAR T-Cell Therapies: Patent Valuation

12. CASE STUDY: CELL THERAPY MANUFACTURING
12.1. Chapter Overview
12.2. Overview of Cell Therapy Manufacturing
12.3. Cell Therapy Manufacturing Models
12.3.1. Centralized Manufacturing Model
12.3.2. Decentralized Manufacturing Model
12.4. Scalability of Cell Therapy Manufacturing Processes
12.4.1. Scale-Up
12.4.2. Scale-Out
12.5. Types of Cell Therapy Manufacturers
12.6. Key Challenges Related to Manufacturing of Cell Therapies
12.7. Key Considerations for Cell Therapy Manufacturing
12.7.1. Characterization
12.7.2. Cost of Goods
12.8. Automation of Cell Therapy Manufacturing Process
12.9. Cell Therapy Manufacturing Supply Chain
12.10. Comparison of Players Having In-House Capabilities and Contract Manufacturers
12.11. Regulatory Landscape
12.12. Future Perspectives

13. COST PRICE ANALYSIS
13.1. Chapter Overview
13.2. Factors Contributing to the High Price of Cell / Gene Therapies
13.3. Pricing Models for T-Cell Immunotherapies
13.3.1. Based on Associated Costs
13.3.2. Based on Availability of Competing Products
13.3.3. Based on Patient Segment
13.3.4. Based on Opinions of Industry Experts
13.4. Reimbursement related Considerations for T-cell Immunotherapies
13.4.1. Case Study: The National Institute for Health and Care Excellence (NICE) Appraisal of CAR-T therapies

14. MARKET FORECAST AND OPPORTUNITY ANALYSIS
14.1. Chapter Overview
14.2. Scope and Limitations
14.3. Key Assumptions and Forecast Methodology
14.4. Global CAR T Cell Therapy Market, 2022-2035
14.4.1. CAR T Cell Therapy Market: Analysis by Target Indication
14.4.2. CAR T Cell Therapy Market: Analysis by Target Antigen
14.4.3. CAR T Cell Therapy Market: Analysis by Key Players
14.4.4. CAR T Cell Therapy Market: Analysis by Geography
14.4.5. Product Wise Sales Forecast
14.4.5.1. Kymriah / Tisagenlecleucel / CTL019 (Novartis)
14.4.5.1.1. Sales Forecast (USD Million)
14.4.5.1.2. Net Present Value
14.4.5.1.3. Value Creation Analysis

14.4.5.2. Yescarta / Axiscabtagene Ciloleucel / KTE-C19 (Gilead Sciences)
14.4.5.2.1. Sales Forecast (USD Million)
14.4.5.2.2. Net Present Value (USD Million)
14.4.5.2.3. Value Creation Analysis

14.4.5.3. Tecartus / Brexucabtagene Autoleucel (Gilead Sciences)
14.4.5.3.1. Sales Forecast (USD Million)
14.4.5.3.2. Net Present Value (USD Million)
14.4.5.3.3. Value Creation Analysis

14.4.5.4. Abecma / BB2121 / Idecabtagene Vicleucel (Bristol Myers Squibb)
14.4.5.4.1. Sales Forecast (USD Million)
14.4.5.4.2. Net Present Value (USD Million)
14.4.5.4.3. Value Creation Analysis

14.4.5.5. Carvykti / Ciltacabtagene Autoleucel / LCAR-B38M CAR-T / JNJ-68284528 (Janssen)
14.4.5.5.1. Sales Forecast (USD Million)
14.4.5.5.2. Net Present Value (USD Million)
14.4.5.5.3. Value Creation Analysis

14.4.5.6. Breyanzi / Lisocabtagene Maraleucel / JCAR017 (Bristol Myers Squibb)
14.4.5.6.1. Sales Forecast (USD Million)
14.4.5.6.2. Net Present Value (USD Million)
14.4.5.6.3. Value Creation Analysis

14.4.5.7. Carteyva / Relmacabtagene Autoleucel / JWCAR029 (JW Therapeutics)
14.4.5.7.1. Sales Forecast (USD Million)
14.4.5.7.2. Net Present Value (USD Million)
14.4.5.7.3. Value Creation Analysis

14.4.5.8. BCMA CAR-T Cells (Shanghai Unicar-Therapy Bio-medicine Technology)
14.4.5.8.1. Sales Forecast (USD Million)
14.4.5.8.2. Net Present Value (USD Million)
14.4.5.8.3. Value Creation Analysis

14.4.5.9. CD19 CAR-T (Wuhan Si'an Medical Technology)
14.4.5.9.1. Sales Forecast (USD Million)
14.4.5.9.2. Net Present Value (USD Million)
14.4.5.9.3. Value Creation Analysis

14.4.5.10. Descartes-11 (Cartesian Therapeutics)
14.4.5.10.1. Sales Forecast (USD Million)
14.4.5.10.2. Net Present Value (USD Million)
14.4.5.10.3. Value Creation Analysis

14.4.5.11. Descartes-08 (Cartesian Therapeutics)
14.4.5.11.1. Sales Forecast (USD Million)
14.4.5.11.2. Net Present Value (USD Million)
14.4.5.11.3. Value Creation Analysis

14.4.5.12. Zamtocabtagene Autoleucel MB-CART19.1 (Miltenyi Biomedicine)
14.4.5.12.1. Sales Forecast (USD Million)
14.4.5.12.2. Net Present Value (USD Million)
14.4.5.12.3. Value Creation Analysis

14.4.5.13. CNCT19 / HY001 (Juventas Cell Therapy)
14.4.5.13.1. Sales Forecast (USD Million)
14.4.5.13.2. Net Present Value (USD Million)
14.4.5.13.3. Value Creation Analysis

14.4.5.14. CD30.CAR-T / TT11 (Tessa Therapeutics)
14.4.5.14.1. Sales Forecast (USD Million)
14.4.5.14.2. Net Present Value (USD Million)
14.4.5.14.3. Value Creation Analysis

14.4.5.15. TAK-007 (Takeda)
14.4.5.15.1. Sales Forecast (USD Million)
14.4.5.15.2. Net Present Value (USD Million)
14.4.5.15.3. Value Creation Analysis

14.4.5.16. AUTO1 (Autolus)
14.4.5.16.1. Sales Forecast (USD Million)
14.4.5.16.2. Net Present Value (USD Million)
14.4.5.16.3. Value Creation Analysis

14.4.5.17. AUTO3 (Autolus)
14.4.5.17.1. Sales Forecast (USD Million)
14.4.5.17.2. Net Present Value (USD Million)
14.4.5.17.3. Value Creation Analysis
14.4.5.18. CD19 CAR-T (Bioray Laboratories)
14.4.5.18.1. Sales Forecast (USD Million)
14.4.5.18.2. Net Present Value (USD Million)
14.4.5.18.3. Value Creation Analysis

14.4.5.19. Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology)
14.4.5.19.1. Sales Forecast (USD Million)
14.4.5.19.2. Net Present Value (USD Million)
14.4.5.19.3. Value Creation Analysis

14.4.5.20. IM19 CAR-T (Beijing Immunochina Medical Science & Technology)
14.4.5.20.1. Sales Forecast (USD Million)
14.4.5.20.2. Net Present Value (USD Million)
14.4.5.20.3. Value Creation Analysis

14.4.5.21. CCT301 CAR-T Cell Therapy (Shanghai Sinobioway Sunterra Biotech)
14.4.5.21.1. Sales Forecast (USD Million)
14.4.5.21.2. Net Present Value (USD Million)
14.4.5.21.3. Value Creation Analysis

14.4.5.22. BinD19 (Shenzhen BinDeBio)
14.4.5.22.1. Sales Forecast (USD Million)
14.4.5.22.2. Net Present Value (USD Million)
14.4.5.22.3. Value Creation Analysis

14.4.5.23. CARCIK-CD19 (CoImmune)
14.4.5.23.1. Sales Forecast (USD Million)
14.4.5.23.2. Net Present Value (USD Million)
14.4.5.23.3. Value Creation Analysis

14.4.5.24. PBCAR269A (Precision BioSciences / Servier)
14.4.5.24.1. Sales Forecast (USD Million)
14.4.5.24.2. Net Present Value (USD Million)
14.4.5.24.3. Value Creation Analysis

14.4.5.25. CD123 CAR-T cells Therapy (Chongqing Precision Biotechnology)
14.4.5.25.1. Sales Forecast (USD Million)
14.4.5.25.2. Net Present Value (USD Million)
14.4.5.25.3. Value Creation Analysis

14.4.5.26. BCMA CAR-T (Chongqing Precision Biotech)
14.4.5.26.1. Sales Forecast (USD Million)
14.4.5.26.2. Net Present Value (USD Million)
14.4.5.26.3. Value Creation Analysis

14.4.5.27. CD19/CD22-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology)
14.4.5.27.1. Sales Forecast (USD Million)
14.4.5.27.2. Net Present Value (USD Million)
14.4.5.27.3. Value Creation Analysis

14.4.5.28. GC012F / Dual CAR-BCMA-19 (Gracell Biotechnology)
14.4.5.28.1. Sales Forecast (USD Million)
14.4.5.28.2. Net Present Value (USD Million)
14.4.5.28.3. Value Creation Analysis

14.4.5.29. iC9-CAR19 T cells (Bellicum Pharmaceuticals)
14.4.5.29.1. Sales Forecast (USD Million)
14.4.5.29.2. Net Present Value (USD Million)
14.4.5.29.3. Value Creation Analysis

14.4.5.30. ALLO-501A / ALLO-501 (Allogene Therapeutics)
14.4.5.30.1. Sales Forecast (USD Million)
14.4.5.30.2. Net Present Value (USD Million)
14.4.5.30.3. Value Creation Analysis

14.4.5.31. CD19/CD20-CAR-T (Yake Biotechnology)
14.4.5.31.1. Sales Forecast (USD Million)
14.4.5.31.2. Net Present Value (USD Million)
14.4.5.31.3. Value Creation Analysis

14.4.5.32. CD7 CAR-T (PersonGen BioTherapeutics)
14.4.5.32.1. Sales Forecast (USD Million)
14.4.5.32.2. Net Present Value (USD Million)
14.4.5.32.3. Value Creation Analysis

14.4.5.33. Anti-FLT3 CAR-T / TAA05 (PersonGen BioTherapeutics)
14.4.5.33.1. Sales Forecast (USD Million)
14.4.5.33.2. Net Present Value (USD Million)
14.4.5.33.3. Value Creation Analysis

14.4.5.34. CT053 (CARsgen Therapeutics)
14.4.5.34.1. Sales Forecast (USD Million)
14.4.5.34.2. Net Present Value (USD Million)
14.4.5.34.3. Value Creation Analysis

14.4.5.35. Anti-ALPP CAR-T Cells (TCRCure Biopharma)
14.4.5.35.1. Sales Forecast (USD Million)
14.4.5.35.2. Net Present Value (USD Million)
14.4.5.35.3. Value Creation Analysis

14.4.5.36. BCMA targeted prime CAR-T cells (Chongqing Precision Biotechnology)
14.4.5.36.1. Sales Forecast (USD Million)
14.4.5.36.2. Net Present Value (USD Million)
14.4.5.36.3. Value Creation Analysis

14.4.5.37. ALLO-605 (Allogene Therapeutics)
14.4.5.37.1. Sales Forecast (USD Million)
14.4.5.37.2. Net Present Value (USD Million)
14.4.5.37.3. Value Creation Analysis

14.4.5.38. WU CART 007 (Wugen)
14.4.5.38.1. Sales Forecast (USD Million)
14.4.5.38.2. Net Present Value (USD Million)
14.4.5.38.3. Value Creation Analysis

14.4.5.39. CT103A (Nanjing IASO Biotherapeutics)
14.4.5.39.1. Sales Forecast (USD Million)
14.4.5.39.2. Net Present Value (USD Million)
14.4.5.39.3. Value Creation Analysis

15. PROMOTIONAL ANALYSIS
15.1. Chapter Overview
15.2. Channels Used for Promotional Campaigns
15.3. Summary of Product Website Analysis
15.4. Summary of Patient Support Services and Informative Downloads
15.5. Kymriah®: Promotional Analysis
15.5.1. Drug Overview
15.5.2. Product Website Analysis
15.5.2.1. Message for Healthcare Professionals
15.5.2.2. Message for Patients
15.5.2.3. Informative Downloads
15.5.3. Patient Support Services

15.6. Yescarta®: Promotional Analysis
15.6.1. Drug Overview
15.6.2. Product Website Analysis
15.6.2.1. Message for Healthcare Professionals
15.6.2.2. Message for Patients
15.6.2.3. Informative Downloads
15.6.3. Patient Support Services

15.7. Tecartus®: Promotional Analysis
15.7.1. Drug Overview
15.7.2. Product Website Analysis
15.7.2.1. Message for Healthcare Professionals
15.7.2.2. Message for Patients
15.7.2.3. Informative Downloads
15.7.3. Patient Support Services
15.8. Breyanzi®: Promotional Analysis
15.8.1. Drug Overview
15.8.2. Product Website Analysis
15.8.2.1. Message for Healthcare Professionals
15.8.2.2. Message for Patients
15.8.2.3. Informative Downloads
15.8.3. Patient Support Services

15.9. Abecma®: Promotional Analysis
15.9.1. Drug Overview
15.9.2. Product Website Analysis
15.9.2.1. Message for Healthcare Professionals
15.9.2.2. Message for Patients
15.9.2.3. Informative Downloads
15.9.3. Patient Support Services

15.10. Carvykti®: Promotional Analysis
15.10.1. Drug Overview
15.10.2. Product Website Analysis
15.10.2.1. Message for Healthcare Professionals
15.10.2.2. Message for Patients
15.10.2.3. Informative Downloads
15.10.3. Patient Support Services

16. COMPANY PROFILES
16.1. Chapter Overview
16.2. Alaunos Therapeutics
16.3. Autolus
16.4. Bluebird Bio
16.5. Bristol Myers Squibb
16.6. Carsgen Therapeutics
16.7. Cellectis
16.8. Cellular Biomedicine Group
16.9. Gilead Sciences
16.10. Innovative Cellular Therapeutics
16.11. Kuur Therapeutics
16.12. Noile-Immune Biotech
16.13. Novartis
16.14. Shanghai GeneChem
16.15. Sinobioway Cell Therapy
16.16. Takara Bio
16.17. Wellington Zhaotai Therapies

17. CONCLUDING REMARKS

18. EXECUTIVE INSIGHTS
18.1. Chapter Overview
18.2. Glycostem Therapeutics
18.2.1. Interview Transcript: Troels Jordansen, Chief Executive Officer

18.2. Gracell Biotechnologies
18.2.1. Interview Transcript: Wei (William) Cao, Chief Executive Officer

18.3. TxCell
18.3.1. Interview Transcript: Miguel Forte, Chief Operating Officer
18.4. Kite Pharma
18.4.1. Interview Transcript: Adrian Bot, Vice President, Scientific Affairs

18.5. Celyad
18.5.1. Interview Transcript: Vincent Brichard, Vice President, Immuno-Oncologys

18.6. Waisman Biomanufacturing
18.6.1. Interview Transcript: Brian Dattilo, Manager of Business Development

18.7. Theravectys
18.7.1. Interview Transcript: Aino Kalervo, Former Competitive Intelligence Manager, Strategy & Business Development

18.8. Changhai Hospital
18.8.1. Interview Transcript: Xian-Bao Zhan, Professor of Medicine and Director, Department of Oncology

18.9. University of Colorado
18.9.1. Interview Transcript: Enkhtsetseg Purev, Assistant Professor of Medicine

19. APPENDIX 1: TABULATED DATA

20. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 2.1 Executive Summary: Overall Market Landscape
Figure 2.1 Executive Summary: Overall Market Landscape
Figure 2.2 Executive Summary: Clinical Trial Analysis
Figure 2.3 Executive Summary: Partnerships and Collaborations
Figure 2.4 Executive Summary: Funding and Investments
Figure 2.5 Executive Summary: Patent Analysis
Figure 2.6 Executive Summary: Market Forecast and Opportunity Analysis
Figure 3.1 Pillars of Cancer Therapy
Figure 3.2 Differences between Active and Passive Immunotherapies
Figure 3.3 Differences between Specific and Non-Specific Immunotherapies
Figure 3.4 Strategies Employed for the Redirection of T-Cells
Figure 3.5 T-Cell Manufacturing: General Procedure
Figure 3.6 Development History of CAR-T cells
Figure 3.7 Structure of Chimeric Antigen Receptor
Figure 3.8 Chimeric Antigen Receptors: Structural Variations across Different Generations
Figure 3.9 CAR T-Cell Therapies: Development Process
Figure 3.10 Challenges Associated with CAR T-Cell Therapies
Figure 4.1 CAR T Cell Therapy: Distribution by Type of Developer
Figure 4.2 CAR T Cell Therapy: Distribution by Phase of Development
Figure 4.3 CAR T Cell Therapy: Distribution by Therapeutic Area
Figure 4.4 CAR T Cell Therapy: Distribution by Phase of Development and Therapeutic Area
Figure 4.5 CAR T Cell Therapy: Distribution by Key Target Indication
Figure 4.6 CAR T Cell Therapy: Distribution by Key Target Antigen
Figure 4.7 CAR T Cell Therapy: Distribution by Source of T-Cells
Figure 4.8 CAR T Cell Therapy: Distribution by Phase of Development and Source of T-Cells
Figure 4.9 CAR T Cell Therapy: Distribution by Route of Administration
Figure 4.10 CAR T Cell Therapy: Distribution by Dosing Frequency
Figure 4.11 CAR T Cell Therapy: Distribution by Target Patient Segment
Figure 4.12 CAR T Cell Therapy: Distribution by Type of Therapy
Figure 4.13 Most Active Industry Players: Analysis by Number of CAR-T Cell Therapies
Figure 4.14 Most Active Non-Industry Players: Distribution by Number of CAR-T Cell Therapies
Figure 4.15 CAR-T Cell Therapy Developers Distribution by Year of Establishment
Figure 4.16 CAR-T Cell Therapy Developers: Distribution by Company Size
Figure 4.17 CAR-T Cell Therapy Developers: Distribution by Location of Headquarters (Region-wise)
Figure 4.18 CAR T Cell Therapy: Distribution by Location of Headquarters (Country-wise)
Figure 5.1 CAR T Cell Therapy: Popular Targets in Hematological Malignancies
Figure 5.2 CAR T Cell Therapy: Popular Targets in Solid Tumors
Figure 5.3 CAR-Construction: Distribution by Generation of CAR
Figure 5.4 CAR-Construction: Distribution by Type of scFv Antibody
Figure 5.5 CAR-Construction: Distribution by Type of Virus Used
Figure 5.6 CAR-Construction: Distribution by Type of Gene Transfer Method Used
Figure 5.7 CAR-Construction: Distribution by Type of Co-Stimulatory Domain(s)
Figure 6.1 Clinical Trial Analysis: Scope and Methodology
Figure 6.2 Clinical Trial Analysis: Cumulative Distribution of trials by Trial Registration Year, Pre-2013-2022
Figure 6.3 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year, Pre-2013-2022
Figure 6.4 Clinical Trial Analysis: Distribution by Trial Status
Figure 6.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Pre-2013-2022
Figure 6.6 Clinical Trial Analysis: Distribution of Number of Trials by Trial Phase
Figure 6.7 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Figure 6.8 Clinical Trial Analysis: Distribution by Target Patient
Figure 6.9 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 6.10 Clinical Trial Analysis: Distribution by Study Design
Figure 6.11 Most Active Players: Distribution by Number of Registered Trials
Figure 6.12 Most Active Players: Distribution by Number of Registered Trials
Figure 6.13 Clinical Trial Analysis: Key Focus Areas
Figure 6.14 Clinical Trial Analysis: Distribution of Trials by Geography
Figure 6.15 Clinical Trial Analysis: Distribution of Completed Clinical Trials by Geography
Figure 6.16 Clinical Trial Analysis: Distribution of Active Clinical Trials by Geography
Figure 6.17 Clinical Trial Analysis: Distribution of Patients Enrolled by Geography
Figure 7.1 CAR T-Cell Therapies KOL Analysis: Distribution by Type of Organization
Figure 7.2 CAR T-Cell Therapies KOL Analysis: Distribution by Affiliated Organization
Figure 7.3 CAR T-Cell Therapies KOL Analysis: Distribution by Qualification
Figure 7.4 CAR T-Cell Therapies: Geographical Distribution of KOLs
Figure 7.5 CAR T-Cell Therapies Scatter Plot: KOL Activenes s versus KOL Strength
Figure 7.6 Most Prominent KOLs: KOL Activeness versus KOL Strength
Figure 7.7 Most Prominent KOLs: Distribution by RA Score
Figure 7.8 Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Figure 7.9 Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Figure 8.1 Kymriah / Tisagenlecleucel: Estimated Sales Revenues
Figure 8.2 Yescarta / Axicabtagene Ciloleucel: Estimated Sales Revenues
Figure 8.3 Tecartus / Brexucabtagene Autoleucel: Estimated Sales Revenues
Figure 8.4 Breyanzi / Lisocabtagene Maraleucel: Estimated Sales Revenues
Figure 8.5 Abecma / Idecabtagene Vicleucel: Estimated Sales Revenues
Figure 8.6 Carvykti / Ciltacabtagene Autoleucel: Estimated Sales Revenues
Figure 8.7 Carteyva / Relmacabtagene Autoleucel: Estimated Sales Revenues
Figure 8.8 AUTO1: Estimated Sales Revenues
Figure 8.9 AUTO3: Estimated Sales Revenues
Figure 9.1 Partnerships and Collaborations: Cumulative Year-Wise Trend, Pre-2015-2022
Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3 Partnerships and Collaborations: Distribution by Type of Partnership, Pre-2015 and 2015-2022
Figure 9.4 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership
Figure 9.5 Partnerships and Collaborations: Distribution by Type of partner
Figure 9.6 Partnerships and Collaborations: Year-Wise Distribution by Type of Partner, Pre-2015-2022
Figure 9.7 Most Popular Products: Distribution by Number of Partnerships
Figure 9.8 Most Active Industry Players: Distribution by Number of Partnerships
Figure 9.9 Most Active Non-Industry Players: Distribution by Number of Partnerships
Figure 9.10 Partnerships and Collaborations: Distribution of Intercontinental and Intracontinental Deals
Figure 9.11 Partnerships and Collaborations: Distribution of International and Local Deals
Figure 10.1 Funding and Investment Analysis: Cumulative Distribution of Instances by Year, Pre-2018 - 2022
Figure 10.2 Funding and Investment Analysis: Cumulative Distribution of Amount Invested by Year, Pre-2018 - 2022 (USD Million)
Figure 10.3 Funding and Investment Analysis: Distribution of Instances by Type of Funding
Figure 10.4 Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding (USD Million)
Figure 10.5 Funding and Investments: Distribution by Types of Investors
Figure 10.6 Funding and Investments: Distribution of Amount Invested by Type of Investor (USD Million)
Figure 10.7 Most Active Players: Distribution by Number of Instances
Figure 10.8 Most Active Players: Distribution by Amount Invested (USD Million
Figure 10.9 Funding and Investment Analysis: Distribution of Amount Invested by Geography
Figure 11.1 Patent Analysis: Distribution by Type of Patent
Figure 11.2 Patent Analysis: Cumulative Distribution by Patent Publication Year
Figure 11.3 Patent Analysis: Cumulative Distribution Patent Application Year
Figure 11.4 Patent Analysis: Cumulative Distribution by Annual Granted Patents
Figure 11.5 Patent Analysis: Cumulative Distribution of Year-wise Filed Patent Applications
Figure 11.6 Patent Analysis: Distribution of Year-wise Granted Patents and Patent Applications
Figure 11.7 Patent Analysis: Distribution by Geography
Figure 11.8 Patent Analysis: Distribution by Type of Player
Figure 11.9 Patent Analysis: Distribution by CPC Symbols
Figure 11.10 Patent Analysis: Key Focus Area
Figure 11.11 Leading Industry Players: Distribution by Number of Patents
Figure 11.12 Leading Non-Industry Players: Distribution by Number of Patents
Figure 11.13 Leading Patent Assignees: Distribution by Number of Patents
Figure 11.14 Patent Analysis (Top 9 CPC Symbols): Benchmarking by Leading Players
Figure 11.15 Patent Analysis: Distribution by Patent Age
Figure 11.14 CAR T Cell Therapy: Patent Valuation Analysis
Figure 12.1 Steps for Manufacturing Cell Therapies
Figure 12.2 Centralized Manufacturing: Process Model
Figure 12.3 Decentralized Manufacturing: Process Model
Figure 12.4 Cell Therapy Manufacturing: Types of Manufacturers
Figure 12.5 Cell Therapy: Challenges and Drivers
Figure 12.6 Cell Therapies: Potency as Critical Quality Attribute
Figure 12.7 Cell Therapy Manufacturing: Supply Chain Model
Figure 12.8 Cell Therapy Manufacturing: Supply Chain Risk Assessment Considerations
Figure 13.1 Approved T-Cell Therapies: Pricing Model based on Patient Segment
Figure 14.1 Global CAR T Cell Therapy Market, 2022-2035 (USD Billion)
Figure 14.2 CAR T Cell Therapy Market: Distribution by Target Indication(s), 2025 and 2035 (USD Billion)
Figure 14.3 CAR T Cell Therapy Market: Distribution by Target Antigen(s), 2025 and 2035 (USD Billion)
Figure 14.4 CAR T Cell Therapy Market: Distribution by Key Players, 2025 and 2035 (USD Billion)
Figure 14.5 CAR T Cell Therapy Market: Distribution by Geography, 2025 and 2035 (USD Billion)
Figure 14.6 Kymriah® / Tisagenlecleucel / CTL019 (Novartis) Sales Forecast, till 2035 (USD Million)
Figure 14.7 Yescarta / Axiscabtagene Ciloleucel / KTE-C19 (Gilead Sciences) Sales Forecast, till 2035 (USD Million)
Figure 14.8 Tecartus / Brexucabtagene Autoleucel (Gilead Sciences) Sales Forecast, till 2035 (USD Million)
Figure 14.9 Abecma / BB2121 / Idecabtagene Vicleucel (Bristol Myers Squibb) Sales Forecast, till 2035 (USD Million)
Figure 14.10 Carvykti / Ciltacabtagene Autoleucel / LCAR-B38M CAR-T / JNJ-68284528 (Janssen) Sales Forecast, till 2035 (USD Million)
Figure 14.11 Breyanzi / Lisocabtagene Maraleucel / JCAR017 (Bristol Myers Squibb) Sales Forecast, till 2035 (USD Million)
Figure 14.12 Carteyva / Relmacabtagene Autoleucel / JWCAR029 (JW Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 14.13 BCMA CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology) Sales Forecast, till 2035 (USD Million)
Figure 14.14 CD19 CAR-T (Wuhan Si'an Medical Technology) Sales Forecast, till 2035 (USD Million)
Figure 14.15 Descartes-11 (Cartesian Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 14.16 Descartes-08 (Cartesian Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 14.17 Zamtocabtagene Autoleucel MB-CART19.1 (Miltenyi Biomedicine) Sales Forecast, till 2035 (USD Million)
Figure 14.18 CNCT19 / HY001 (Juventas Cell Therapy) Sales Forecast, till 2035 (USD Million)
Figure 14.19 CD30.CAR-T / TT11 (Tessa Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 14.20 TAK-007 (Takeda) Sales Forecast, till 2035 (USD Million)
Figure 14.21 AUTO1 (Autolus) Sales Forecast, till 2035 (USD Million)
Figure 14.22 AUTO3 (Autolus) Sales Forecast, till 2035 (USD Million)
Figure 14.23 CD19 CAR-T (Bioray Laboratories) Sales Forecast, till 2035 (USD Million)
Figure 14.24 Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology, till 2035 (USD Million)
Figure 14.25 IM19 CAR-T (Beijing Immunochina Medical Science & Technology) Sales Forecast, till 2035 (USD Million)
Figure 14.26 CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech) Sales Forecast, till 2035 (USD Million)
Figure 14.27 BinD19 (Shenzhen BinDeBio) Sales Forecast, till 2035 (USD Million)
Figure 14.28 CARCIK-CD19 (CoImmune) Sales Forecast, till 2035 (USD Million)
Figure 14.29 PBCAR269A (Precision BioSciences / Servier) Sales Forecast, till 2035 (USD Million)
Figure 14.30 CD123 CAR-T cells (Chongqing Precision Biotechnology) Sales Forecast, till 2035 (USD Million)
Figure 14.31 BCMA CAR-T (Chongqing Precision Biotech) Sales Forecast, till 2035 (USD Million)
Figure 14.32 CD19/CD22-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology) Sales Forecast, till 2035 (USD Million)
Figure 14.33 GC012F / DUAL CAR-BCMA-19 (Gracell Biotechnology) Sales Forecast, till 2035 (USD Million)
Figure 14.34 IC9-CAR19 T Cells (Bellicum Pharmaceuticals) Sales Forecast, till 2035 (USD Million)
Figure 14.35 ALLO-501A / ALLO-501 (Allogene Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 14.36 CD19/CD20-CAR-T (Yake Biotechnology) Sales Forecast, till 2035 (USD Million)
Figure 14.37 CD7 CAR-T (PersonGen BioTherapeutics) Sales Forecast, till 2035 (USD Million)
Figure 14.38 Anti-FLT3 CAR-T / TAA05 (PersonGen BioTherapeutics) Sales Forecast, till 2035 (USD Million)
Figure 14.39 CT053 (CARsgen Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 14.40 Anti-ALPP CAR-T Cells (TCRCure Biopharma) Sales Forecast, till 2035 (USD Million)
Figure 14.41 BCMA targeted prime CAR-T cells (Chongqing Precision Biotechnology) Sales Forecast, till 2035 (USD Million)
Figure 14.42 ALLO-605 (Allogene Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 14.43 WU CART 007 (WUGEN) Sales Forecast, till 2035 (USD Million)
Figure 14.44 CT103A (Nanjing IASO Biotherapeutics) Sales Forecast, till 2035 (USD Million)
Figure 15.1 Channels Used for Promotional Campaigns
Figure 15.2 Promotional / Marketing Strategy: Product Website Analysis
Figure 15.3 Product Website Analysis: Kymriah, Messages for Healthcare Professionals
Figure 15.4 Product Website Analysis: Kymriah, Messages for Patients
Figure 15.5 Product Website Analysis: Kymriah, Patient Support Program
Figure 15.6 Product Website Analysis: Yescarta, Messages for Healthcare Professionals
Figure 15.7 Product Website Analysis: Yescarta, Messages for Patients
Figure 15.8 Product Website Analysis: Yescarta, Kite Konnect
Figure 15.9 Product Website Analysis: Yescarta, Platform for Referral Patient Treatment and Connecting with Treatment Center
Figure 15.10 Product Website Analysis: Tecartus, Messages for Healthcare Professionals
Figure 15.11 Product Website Analysis: Tecartus, Messages for Patients
Figure 15.12 Product Website Analysis: Tecartus, Kite Konnect
Figure 15.13 Product Website Analysis: Breyanzi, Messages for Healthcare Professional
Figure 15.14 Product Website Analysis: Breyanzi, Messages for Patients
Figure 15.15 Product Website Analysis: Breyanzi, Cell Therapy 360
Figure 15.16 Product Website Analysis: Abecma, Messages for Healthcare Professional
Figure 15.17 Product Website Analysis: Abecma, Messages for Patients
Figure 15.18 Product Website Analysis: Abecma, Cell Therapy 360
Figure 15.19 Product Website Analysis: Carvykti, Messages for Healthcare Professional
Figure 15.20 Product Website Analysis: Carvykti, Messages for Patients
Figure 15.21 Product Website Analysis: Carvykti, MyCARVYKTI
Figure 17.1 Concluding Remarks: Market Landscape
Figure 17.2 Concluding Remarks: Clinical Trial Analysis
Figure 17.3 Concluding Remarks: Key Opinion Leaders
Figure 17.4 Concluding Remarks: Partnerships & Collaborations
Figure 17.5 Concluding Remarks: Funding and Investment Analysis
Figure 17.6 Concluding Remarks: Patent Analysis
Figure 17.7 Concluding Remarks: Market Forecast

List Of Tables

Table 2.1 Biosensors in Drug Discovery: List of Companies
Table 3.1 Types of Immunotherapies and Affiliated Mechanisms of Action
Table 3.2 FDA Approved Antibody based Cancer Therapeutics
Table 3.5 Key Characteristics of CAR-T Cells
Table 3.6 Comparison of First and Second-Generation CAR-Ts
Table 3.7 CD19 CAR-T Cells: Preclinical Results
Table 3.8 Other Targets under Clinical / Preclinical Studies for CAR-T Cell Therapies
Table 4.1 CAR T Cell Therapy: Clinical Pipeline
Table 4.2 CAR T Cell Therapy: Information on Route of Administration, Source of T-Cells, Target Patient Segment, Type of Therapy and Dosing Frequency
Table 4.3 CAR T Cell Therapy: Preclinical Pipeline
Table 4.4 List of CAR-T Cells Developers
Table 5.1 CAR-T Therapies: Information on Constructs of Clinical Candidates
Table 8.1 CAR T Cell Therapy: List of Therapies Profiled
Table 8.2 Therapy Profile: Kymriah® / Tisagenlecleucel (Novartis)
Table 8.3 Kymriah / Tisagenlecleucel: Clinical Trial Information
Table 8.4 Kymriah / Tisagenlecleucel: Clinical Trial Endpoints
Table 8.5 Kymriah / Tisagenlecleucel: Clinical Trial Results
Table 8.6 Therapy Profile: Yescarta / Axiscabtagene Ciloleucel (Gilead Sciences)
Table 8.7 Yescarta / Axiscabtagene Ciloleucel: Clinical Trial Information
Table 8.8 Yescarta / Axiscabtagene Ciloleucel: Clinical Trial Endpoints
Table 8.9 Yescarta / Axiscabtagene Ciloleucel: Clinical Trial Results
Table 8.10 Therapy Profile: Tecartus / Brexucabtagene Autoleucel (Gilead Sciences)
Table 8.11 Tecartus / Brexucabtagene Autoleucel: Clinical Trial Information
Table 8.12 Tecartus / Brexucabtagene Autoleucel: Clinical Trial Endpoints
Table 8.13 Tecartus / Brexucabtagene Autoleucel: Clinical Trial Results
Table 8.14 Therapy Profile: Breyanzi / Lisocabtagene Maraleucel (Bristol Myers Squibb)
Table 8.15 Breyanzi / Lisocabtagene Maraleucel: Clinical Trial Information
Table 8.16 Breyanzi / Lisocabtagene Maraleucel: Clinical Trial Endpoints
Table 8.17 Breyanzi / Lisocabtagene Maraleucel: Clinical Trial Results
Table 8.18 Therapy Profile: Abecma / Idecabtagene Vicleucel (Bristol Myers Squibb)
Table 8.19 Abecma / Idecabtagene Vicleucel: Clinical Trial Information
Table 8.20 Abecma / Idecabtagene Vicleucel: Clinical Trial Endpoints
Table 8.21 Abecma / Idecabtagene Vicleucel: Clinical Trial Results
Table 8.22 Therapy Profile: Carvykti / Ciltacabtagene Autoleucel (Janssen)
Table 8.23 Carvykti / Ciltacabtagene Autoleucel: Clinical Trial Information
Table 8.24 Carvykti / Ciltacabtagene Autoleucel: Clinical Trial Endpoints
Table 8.25 Carvykti / Ciltacabtagene Autoleucel: Clinical Trial Results
Table 8.26 Therapy Profile: Carteyva / Relmacabtagene Autoleucel (JW Therapeutics)
Table 8.27 Carteyva / Relmacabtagene Autoleucel: Clinical Trial Information
Table 8.28 Carteyva / Relmacabtagene Autoleucel: Clinical Trial Endpoints
Table 8.29 Carteyva / Relmacabtagene Autoleucel: Clinical Trial Results
Table 8.30 Therapy Profile: TBI-1501 (Takara Bio)
Table 8.31 TBI-1501: Clinical Trial Information
Table 8.32 TBI-1501: Clinical Trial Endpoints
Table 8.33 Therapy Profile: AUTO1 (Autolus)
Table 8.34 AUTO1: Clinical Trial Information
Table 8.35 AUTO1: Clinical Trial Endpoints
Table 8.36 AUTO1: Clinical Trial Results
Table 8.37 Therapy Profile: AUTO3 (Autolus)
Table 8.38 AUTO3: Clinical Trial Information
Table 8.39 AUTO3: Clinical Trial Endpoints
Table 8.40 AUTO3: Clinical Trial Results
Table 9.1 CAR T Cell Therapy: List of Partnerships and Collaborations, 2005-2022
Table 10.1 CAR T Cell Therapy: Funding and Investments, 2000-2022
Table 10.2 CAR T Cell Therapy: Summary of Investments
Table 11.1 Patent Analysis: Prominent CPC Symbols
Table 11.2 Patent Analysis: Most Popular CPC Symbols
Table 11.3 Patent Analysis: List of Top CPC Symbols
Table 11.4 Patent Analysis: Summary of Benchmarking Analysis
Table 11.5 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 12.1 Assessment Strategies for Different Manufacturing Processes
Table 12.2 Advantages and Disadvantages of Centralized and Decentralized Manufacturing Models
Table 12.3 Cell Therapy Manufacturing: Companies with In-House Capabilities and Contract Manufacturers
Table 13.1 Price of Marketed Gene / Cell Therapies
Table 13.2 Price of Marketed Targeted Drugs
Table 13.3 CAR T Cell Therapy: Expert Opinions on Pricing
Table 13.4 CAR T Cell Therapy: Reimbursement Landscape
Table 14.1 CAR T Cell Therapy: List of Forecasted Molecules
Table 14.2 Kymriah / Tisagenlecleucel (Novartis): Net Present Value (USD Million)
Table 14.3 Kymriah / Tisagenlecleucel (Novartis): Value Creation Analysis (USD Million)
Table 14.4 Yescarta / Axiscabtagene Ciloleucel (Gilead Sciences): Net Present Value (USD Million)
Table 14.5 Yescarta / Axiscabtagene Ciloleucel (Gilead Sciences): Value Creation Analysis (USD Million)
Table 14.6 Tecartus / Brexucabtagene Autoleucel: (Gilead Sciences): Net Present Value (USD Million)
Table 14.7 Tecartus / Brexucabtagene Autoleucel: (Gilead Sciences): Value Creation Analysis (USD Million)
Table 14.8 Abecma / BB2121 / Idecabtagene Vicleucel (Bristol Myers Squibb): Net Present Value (USD Million)
Table 14.9 Abecma / BB2121 / Idecabtagene Vicleucel (Bristol Myers Squibb): Value Creation Analysis (USD Million)
Table 14.10 Carvykti / Ciltacabtagene Autoleucel / LCAR-B38M (Nanjing Legend Biotech /Janssen): Net Present Value (USD Million)
Table 14.11 Carvykti / Ciltacabtagene Autoleucel / LCAR-B38M (Nanjing Legend Biotech /Janssen): Value Creation Analysis (USD Million)
Table 14.12 Breyanzi / Lisocabtagene Maraleucel / JCAR017 (Bristol Myers Squibb): Net Present Value (USD Million)
Table 14.13 Breyanzi / Lisocabtagene Maraleucel / JCAR017 (Bristol Myers Squibb): Value Creation Analysis (USD Million)
Table 14.14 Carteyva / Relmacabtagene Autoleucel / JWCAR029 (JW Therapeutics): Net Present Value (USD Million)
Table 14.15 Carteyva / Relmacabtagene Autoleucel / JWCAR029 (JW Therapeutics): Value Creation Analysis (USD Million)
Table 14.16 BCMA CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Net Present Value (USD Million)
Table 14.17 BCMA CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Value Creation Analysis (USD Million)
Table 14.18 CD19 CAR-T (Wuhan Si'an Medical Technology): Net Present Value (USD Million)
Table 14.19 CD19 CAR-T (Wuhan Si'an Medical Technology): Value Creation Analysis (USD Million)
Table 14.20 Descartes-11 (Cartesian Therapeutics): Net Present Value (USD Million)
Table 14.21 Descartes-11 (Cartesian Therapeutics): Value Creation Analysis (USD Million)
Table 14.22 Descartes-08 (Cartesian Therapeutics): Net Present Value (USD Million)
Table 14.23 Descartes-08 (Cartesian Therapeutics): Value Creation Analysis (USD Million)
Table 14.24 Zamtocabtagene Autoleucel MB-CART19.1 (Miltenyi Biomedicine): Net Present Value (USD Million)
Table 14.25 Zamtocabtagene Autoleucel MB-CART19.1 (Miltenyi Biomedicine): Value Creation Analysis (USD Million)
Table 14.26 CNCT19 / HY001 (Juventas Cell Therapy): Net Present Value (USD Million)
Table 14.27 CNCT19 / HY001 (Juventas Cell Therapy): Value Creation Analysis (USD Million)
Table 14.28 CD30.CAR-T / TT11 (Tessa Therapeutics): Net Present Value (USD Million)
Table 14.29 CD30.CAR-T / TT11 (Tessa Therapeutics): Value Creation Analysis (USD Million)
Table 14.30 TAK-007 (Takeda): Net Present Value (USD Million)
Table 14.32 TAK-007 (Takeda): Value Creation Analysis (USD Million)
Table 14.33 AUTO1 (Autolus): Net Present Value (USD Million)
Table 14.34 AUTO1 (Autolus): Value Creation Analysis (USD Million)
Table 14.35 AUTO3 (Autolus): Net Present Value (USD Million)
Table 14.36 AUTO3 (Autolus): Value Creation Analysis (USD Million)
Table 14.37 CD19 CAR-T (Bioray Laboratories): Net Present Value (USD Million)
Table 14.38 CD19 CAR-T (Bioray Laboratories): Value Creation Analysis (USD Million)
Table 18.39 Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Net Present Value (USD Million)
Table 20.40 Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Value Creation Analysis (USD Million)
Table 14.41 IM19 CAR-T T (Beijing Immunochina Medical Science & Technology): Net Present Value (USD Million)
Table 14.42 IM19 CAR-T T (Beijing Immunochina Medical Science & Technology): Net Present Value (USD Million)
Table 14.43 CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech): Net Present Value (USD Million)
Table 14.44 CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech): Value Creation Analysis (USD Million)
Table 14.45 BinD19 (Shenzhen BinDeBio): Net Present Value (USD Million)
Table 14.46 BinD19 (Shenzhen BinDeBio): Value Creation Analysis (USD Million)
Table 14.47 CARCIK-CD19 (CoImmune): Net Present Value (USD Million)
Table 14.48 CARCIK-CD19 (Formula Pharmaceuticals): Value Creation Analysis (USD Million)
Table 14.49 PBCAR269A (Precision BioSciences / Servier): Net Present Value (USD Million)
Table 14.50 PBCAR269A (Precision BioSciences and Servier): Value Creation Analysis (USD Million)
Table 14.51 CD123 CAR-T cells (Chongqing Precision Biotechnology): Net Present Value (USD Million)
Table 14.52 CD123 CAR-T cells (Chongqing Precision Biotechnology): Value Creation Analysis (USD Million)
Table 14.53 BCMA CAR-T (Chongqing Precision Biotech): Net Present Value (USD Million)
Table 14.54 BCMA CAR-T (Chongqing Precision Biotech): Value Creation Analysis (USD Million)
Table 14.55 CD19/CD22-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Net Present Value (USD Million)
Table 14.56 CD19/CD22-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Value Creation Analysis (USD Million)
Table 14.57 GC012F / DUAL CAR-BCMA-19 (Gracell Biotechnology): Net Present Value (USD Million)
Table 14.58 GC012F / DUAL CAR-BCMA-19 (Gracell Biotechnology): Value Creation Analysis (USD Million)
Table 14.59 IC9-CAR19 T Cells (Bellicum Pharmaceuticals): Net Present Value (USD Million)
Table 14.60 IC9-CAR19 T Cells (Bellicum Pharmaceuticals): Value Creation Analysis (USD Million)
Table 14.61 ALLO-501A / ALLO-501 (Allogene Therapeutics): Net Present Value (USD Million)
Table 14.62 ALLO-501A / ALLO-501 (Allogene Therapeutics): Value Creation Analysis (USD Million)
Table 14.63 CD19/CD20-CAR-T (Yake Biotechnology): Net Present Value (USD Million)
Table 14.64 CD19/CD20-CAR-T (Yake Biotechnology): Value Creation Analysis (USD Million)
Table 14.65 CD7 CAR-T (PersonGen BioTherapeutics): Net Present Value (USD Million)
Table 14.66 CD7 CAR-T (PersonGen BioTherapeutics): Value Creation Analysis (USD Million)
Table 14.67 Anti-FLT3 CAR-T / TAA05 (PersonGen BioTherapeutics): Net Present Value (USD Million)
Table 14.68 Anti-FLT3 CAR-T / TAA05 (PersonGen BioTherapeutics): Value Creation Analysis (USD Million)
Table 14.69 CT053 (CARsgen Therapeutics): Net Present Value (USD Million)
Table 14.70 CT053 (CARsgen Therapeutics): Value Creation Analysis (USD Million)
Table 14.71 Anti-ALPP CAR-T Cells (TCRCure Biopharma): Net Present Value (USD Million)
Table 14.72 Anti-ALPP CAR-T Cells (TCRCure Biopharma): Value Creation Analysis (USD Million)
Table 14.73 BCMA targeted prime CAR-T cells (Chongqing Precision Biotechnology): Net Present Value (USD Million)
Table 14.74 BCMA targeted prime CAR-T cells (Chongqing Precision Biotechnology): Value Creation Analysis (USD Million)
Table 14.75 ALLO-605 (Allogene Therapeutics): Net Present Value (USD Million)
Table 14.76 ALLO-605 (Allogene Therapeutics): Value Creation Analysis (USD Million)
Table 14.77 WU CART 007 (WUGEN): Net Present Value (USD Million)
Table 14.78 WU CART 007 (WUGEN): Value Creation Analysis (USD Million)
Table 14.79 CT103A (Nanjing IASO Biotherapeutics): Net Present Value (USD Million)
Table 14.80 CT103A (Nanjing IASO Biotherapeutics): Value Creation Analysis (USD Million)
Table 15.1 Promotional / Marketing Strategy: Patient Support Services and Informative Downloads
Table 15.2 Kymriah / Tisagenlecleucel: Drug Overview
Table 15.3 Yescarta / Axiscabtagene Ciloleucel: Drug Overview
Table 15.4 Tecartus / Brexucabtagene Autoleucel: Drug Overview
Table 15.5 Breyanzi / Lisocabtagene Maraleucel: Drug Overview
Table 15.6 Abecma / Idecabtagene Vicleucel: Drug Overview
Table 15.7 Carvykti / Ciltacabtagene Autoleucel: Drug Overview
Table 16.1 Leading CAR-T Cell Therapy Developers
Table 16.2 Autolus: Company Profile
Table 16.3 bluebird bio: Company Profile
Table 16.4 Bristol Myers Squibb: Company Profile
Table 16.5 CARsgen Therapeutics: Company Profile
Table 16.6 Cellectis: Company Profile
Table 16.7 Cellular Biomedicine Group: Company Profile
Table 16.8 Gilead Sciences: Company Profile
Table 16.9 Innovative Cellular Therapeutics: Company Profile
Table 16.10 Kuur Therapeutics: Company Profile
Table 16.11 Noile-Immune Biotech: Company Profile
Table 16.12 Novartis: Company Profile
Table 16.13 Shanghai Genechem: Company Profile
Table 16.14 Sinobioway Cell Therapy: Company Profile
Table 16.15 Takara Bio: Company Profile
Table 16.16 Wellington Zhaotai Therapies: Company Profile
Table 19.1 CAR T Cell Therapy: Distribution by Type of Developer
Table 19.2 CAR T Cell Therapy: Distribution by Phase of Development
Table 19.3 CAR T Cell Therapy: Distribution by Target Therapeutic Area
Table 19.4 CAR T Cell Therapy: Distribution by Phase of Development and Therapeutic Area
Table 19.5 CAR T Cell Therapy: Distribution by Key Target Indications
Table 19.7 CAR T Cell Therapy: Distribution by Source of T-Cells
Table 19.8 CAR T Cell Therapy: Distribution by Phase of Development and Source of T-Cell
Table 19.9 CAR T Cell Therapy: Distribution by Route of Administration
Table 19.10 CAR T Cell Therapy: Distribution by Dosing Frequency
Table 19.11 CAR T Cell Therapy: Distribution by Target Patient Segment
Table 19.12 CAR T Cell Therapy: Distribution by Type of Therapy
Table 19.13 Most Active Industry Players: Distribution by Number of CAR-T Cell Therapies
Table 19.14 Most Active Non-Industry Players: Distribution by Number of CAR-T Cell Therapies
Table 19.15 CAR-T Cell Therapy Developers: Distribution by Year of Establishment
Table 19.16 CAR-T Cell Therapy Developers: Distribution by Company Size
Table 19.17 CAR-T Cell Therapy Developers: Distribution by Location of Headquarters (Region-wise)
Table 19.18 CAR-T Cell Therapy Developers: Distribution by Location of Headquarters (Country-wise)
Table 19.19 CAR T Cell Therapy Clinical Trial Analysis: Cumulative Distribution of Trials by Trial Registration Year
Table 19.20 CAR T Cell Therapy Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population
Table 19.21 CAR T Cell Therapy Clinical Trial Analysis: Distribution by Trial Status
Table 19.22 CAR T Cell Therapy Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Table 19.23 CAR T Cell Therapy Clinical Trial Analysis: Distribution of Number of Trials by Trial Phase
Table 19.24 CAR T Cell Therapy Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Table 19.25 CAR T Cell Therapy Clinical Trial Analysis: Distribution by Target Patient Segment
Table 19.26 CAR T Cell Therapy Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 19.27 CAR T Cell Therapy Clinical Trial Analysis: Distribution by Study Design
Table 19.28 Most Active Industry Players: Distribution by Number of Registered Trials
Table 19.29 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Table 19.30 CAR T Cell Therapy Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Table 19.31 CAR T Cell Therapy Clinical Trial Analysis: Distribution of Completed Clinical Trials by Geography
Table 19.32 CAR-T Cell Therapies Clinical Trial Analysis: Distribution of Active Clinical Trials by Geography
Table 19.33 CAR T Cell Therapy Clinical Trial Analysis: Distribution of Patients Enrolled by Geography
Table 19.34 CAR T Cell Therapy KOL Analysis: Distribution by Type of Organization
Table 19.35 CAR T Cell Therapy KOL Analysis: Distribution by Affiliated Organization
Table 19.36 CAR T Cell Therapy KOL Analysis: Distribution by Qualification
Table 19.37 CAR T Cell Therapy: Geographical Distribution of KOLs
Table 19.38 CAR T Cell Therapy Most Prominent KOLs: Distribution by RA Score
Table 19.39 CAR T Cell Therapy Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Table 19.40 Kymriah / Tisagenlecleucel: Estimated Sales Revenues
Table 19.41 Yescarta / Axicabtagene Ciloleucel: Estimated Sales Revenues
Table 19.42 Tecartus / Brexucabtagene Autoleucel: Estimated Sales Revenues
Table 19.43 Breyanzi / Lisocabtagene Maraleucel: Estimated Sales Revenues
Table 19.44 Abecma / Idecabtagene Vicleucel: Estimated Sales Revenues
Table 19.45 Carvykti / Ciltacabtagene Autoleucel: Estimated Sales Revenues
Table 19.46 Carteyva / Relmacabtagene Autoleucel: Estimated Sales Revenues
Table 19.47 AUTO1: Estimated Sales Revenues
Table 19.48 AUTO3: Estimated Sales Revenues
Table 19.49 Partnerships and Collaborations: Cumulative Year-Wise Trend, Pre-2015-2022
Table 19.50 Partnerships and Collaborations: Distribution by Type of Partnership
Table 19.51 Partnerships and Collaborations: Distribution by Type of Partnership, Pre-2015 and 2015-2022
Table 19.52 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership
Table 19.53 Partnerships and Collaborations: Distribution by Type of Partner
Table 19.54 Partnerships and Collaborations: Year-Wise Distribution by Type of Partner
Table 19.55 Most Popular Products: Distribution by Number of Partnerships
Table 19.56 Most Active Industry Players: Distribution by Number of Partnerships
Table 19.57 Most Active Non-Industry Players: Distribution by Number of Partnerships
Table 19.58 Partnerships and Collaborations: Distribution of Intercontinental and Intracontinental Deals
Table 19.59 Partnerships and Collaborations: Distribution of International and Local Agreements
Table 19.60 Funding and Investment Analysis: Cumulative Distribution of Instances by Year, Pre-2018 – 2022
Table 19.61 Funding and Investment Analysis: Cumulative Distribution of Amount Invested by Year, Pre-2018 -2022 (USD Million)
Table 19.62 Funding and Investment Analysis: Distribution of Instances by Type of Funding
Table 19.63 Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding (USD Million)
Table 19.64 Funding and Investments: Distribution by Type of Investors
Table 19.65 Funding and Investments: Distribution of Amount Invested by Type of Investor (USD Million)
Table 19.66 Most Active Players: Distribution by Number of Instances
Table 19.67 Most Active Players: Distribution by Amount Invested (USD Million)
Table 19.68 Funding and Investment Analysis: Distribution of Amount Invested by Geography
Table 19.69 Most Active Investors: Distribution by Number of Funding Instances
Table 19.70 Patent Analysis: Distribution by Type of Patent
Table 19.71 CAR T Cell Therapy Patent Analysis: Cumulative Distribution by Patent Publication Year
Table 19.72 CAR T Cell Therapy Patent Analysis: Cumulative Distribution by Patent Application Year
Table 19.73 CAR T Cell Therapy Patent Analysis: Cumulative Distribution by Annual Granted Patents
Table 19.74 CAR T Cell Therapy Patent Analysis: Cumulative Distribution of Year-wise Filed Patent Applications
Table 19.75 CAR T Cell Therapy Patent Analysis: Distribution of Year-wise Granted Patents and Patent Applications
Table 19.76 CAR T Cell Therapy Patent Analysis: Distribution by Geography
Table 19.77 CAR T Cell Therapy Patent Analysis: Distribution by Type of Player
Table 19.78 CAR T Cell Therapy Patent Analysis: Distribution by CPC Symbols
Table 19.79 Leading Industry Players: Distribution by Number of Patents
Table 19.80 Leading Non-Industry Players: Distribution by Number of Patents
Table 19.81 Leading Patent Assignees: Distribution by Number of Patents
Table 19.82 Patent Analysis: Distribution by Patent Age
Table 19.83 CAR-T Therapies: Patent Valuation Analysis

List Of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report:

920th Hospital of Joint Logistics Support Force
AbbVie Ventures
AbCellera
AbCheck
AbClon
Abound Bio
Abzena
Ac?badem Atunizade Hospital
Ac?badem Labcell
Acibadem University
ACROBiosystems
AdAlta
Adaptimmune Therapeutics
Adicet Bio
Adimab
Affiliated Hospital of Jiangnan University
Affiliated Hospital of Jiangsu University
Affiliated Hospital to Academy of Military Medical Sciences
Affiliated Zhongshan Hospital of Dalian University
AffyImmune Therapeutics
AGC Biologics
Agreen Biotech
AK (Suzhou) Biomedical
Alaunos Therapeutics
Aleta Biotherapeutics
Alexandria Venture Investments
Allife Medical Science and Technology
Allogene Therapeutics
Alpha Biopharma
Amgen Ventures
Anhui Anke Biotechnology
Anhui Provincial Hospital
Antion Biosciences
Appia Bio
Arbele
Arcellx
Astellas Pharma
Astrazeneca
Atara Biotherapeutics
August Pi and Sunyer Biomedical Research Institute
Aurora Biopharma
Autolus
Avencell
Bambino Gesù Hospital and Research Institute
Bayer
Baylor College of Medicine
Be The Match BioTherapies
Beam Therapeutics
Beijing 302 Hospital
Beijing Biohealthcare Biotechnology
Beijing Boren Hospital
Beijing Cancer Hospital
Beijing Chao Yang Hospital
Beijing Children's Hospital
Beijing Doing Biomedical
Beijing GoBroad Hospital Management
Beijing HuiNengAn Biotech
Beijing Immunochina Medical Science & Technology
Beijing Sanbo Brain Hospital
Beijing Tsinghua Chang Gung Hospital
Beike Biotechnology
Bellicum Pharmaceuticals
Beth Israel Deaconess Medical Center (BIDMC)
Bioceltech Therapeutics
Bio-Gene Technology
BioLife Solutions
Bionomics
BioNTech
Bioray Laboratories
Biosceptre
Bluebird Bio
Boya Jiyin
BoYuan RunSheng Pharma (Hangzhou)
Bristol-Myers Squibb
Cabaletta Bio
Cabaret Biotech
Calibr
California Institute for Regenerative Medicine (CIRM)
Cancer Prevention Research Institute of Texas
Cancer Research Technology
Cancer Research UK
Carbiogene Therapeutics
Caribou Biosciences
Carina Biotech
Caring Cross
Carisma Therapeutics
CARsgen Therapeutics
Cartesian Therapeutics
Cartherics
Case Comprehensive Cancer Center
Celgene
Cell and Gene Therapy Catapult
Cell Design Labs
Cellectis
Cellex Patient Treatment
CELLforCURE
CellPoint
Cellular Biomedicine Group
Cellvec
Celularity
Celyad Oncology
Center for International Blood and Marrow Transplant Research
Central South University
Changhai Hospital
Chengdu USino Technology Biology
Children’s Hospital of Philadelphia
Children's Hospital and Health System Foundation
Children's Hospital of Fudan University
Children's Hospital of Philadelphia
China Immunotech (Beijing) Biotechnology
China Meitan General Hospital
China Regenerative Medicine International (CRMI)
Chinese Academy of Sciences
Chinese PLA General Hospital
Chongqing Precision Biotech
Chongqing Public Health Medical Center
Chongqing Sidemu Biotech
Chongqing University Cancer Hospital
City of Hope Medical Center
CoIMMUNE
Cold Spring Harbor Laboratory
Columbia University
CRISPR Therapeutics
Cryoport
CureSearch for Children's Cancer
Curocell
CytoLumina Technologies
CytoMed Therapeutics
Cytovia Therapeutics
DAIICHI SANKYO COMPANY
Dana-Farber Cancer Institute
Dartmouth College
Delenex Therapeutics
DLR German Aerospace Center
Dongguan People's Hospital
East Clinical Center of Oncology
Eden BioCell
Editas Medicine
Eli Lilly
Elicera Therapeutics
Elpis Biopharmaceuticals
Eureka Therapeutics
Eutilex
EXUMA Biotech
Fate Therapeutics
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Fidelity Management & Research
First Affiliated Hospital of Chengdu Medical College
First Affiliated Hospital of Harbin Medical University
First Affiliated Hospital of Wenzhou Medical Univeristy
First Affiliated Hospital of Wenzhou Medical University
First Affiliated Hospital of Zhejiang University
First Affiliated Hospital Xi'an Jiaotong University
First Hospital of Jilin University
First People's Hospital of Foshan
Five Prime Therapeutics
Fondazione Matilde Tettamanti Menotti De Marchi Onlus
Fondo Social La Caixa
Formula Pharmaceuticals
Fosun Pharmaceutical
Fourth Hospital of Hebei Medical University
Fraunhofer
Fred Hutchinson Cancer Research
Fred Hutchinson Cancer Research Center
Fudan University
Fujian Medical University
Fundamenta Therapeutics
FutureGen Biopharm
G Plus Life Sciences
GE Global Research
GE Healthcare
Genentech
Genus Oncology
Gilead Sciences
Glycostem
GlyTherix
Gracell Biotechnologies
Great Ormond Street Hospital for Children NHS Foundation Trust
Guangdong General Hospital
Guangdong Zhaotai InVivo Biomedicine
Guangzhou 8th People's Hospital
Guangzhou Anjie Biomedical Technology
Guangzhou First People's Hospital
H. Lee Moffitt Cancer Center and Research Institute
Hadassah Medical Organization
Harvard University
HCW Biologics
Hebei Senlang Biotechnology
Hebei Yanda Ludaopei Hospital
Hefei Binhu Hospital
Heidelberg University Hospital
Henan Cancer Hospital
Henan Hualong Biotechnology
Henan Provincial People's Hospital
Hitachi Chemical Advanced Therapeutics Solutions
Horizon 2020
Horizon Discovery Group
Houston Methodist Hospital
Hrain Biotechnology
HuaDao (Shanghai) Biomedical
Huai'an Second People's Hospital
Huazhong University of Science and Technology
Hunan Provincial People's Hospital
Hunan Yongren Medical Innovation
Hunan Zhaotai Yongren Biotech
Hunan Zhaotai Yongren Medical Innovation
IASO Biotherapeutics
iCAR Bio Therapeutics
iCarTAB BioMed
iCell Gene Therapeutics
ICON
IIT MediTech (Jiangsu)
ImmunoACT
Imugene
Inhibrx
Innovative Cellular Therapeutics
Innovent Biologics
Institut Curie
Institute of Hematology & Blood Diseases Hospital
Institute of Hematology and Blood Transfusion
Instituto de Salud Carlos III
Intellia Therapeutics
Intrexon
Invectys
Janssen
Jiangsu Province Hospital of Traditional Chinese Medicine
Jiangyin People's Hospital
Jichi Medical University Hospital
Jingjiang People's Hospital
Jingzhou Central Hospital
Jonsson Comprehensive Cancer Center
Juno Therapeutics
Juventas Cell Therapy
JW Therapeutics
KAEDI
Karolinska Institute
Kecellitics Biotech
King's College London
Kite Pharma (a Gilead Sciences Company)
Kuur Therapeutics
Kyverna Therapeutics
Legend Biotech
Leucid Bio
Leukemia & Lymphoma Society
Leukemia Research Foundation
Life Technologies
Lilly Asia Ventures
Liminatus Pharma
Living Pharma
Lonza
Loyola University Medical Center
LUMICKS
Lyell Immunopharma
MabQuest
Malaghan Institute of Medical Research
Marino Biotechnology
Massachusetts General Hospital
MaSTherCell
Max Delbrück Center for Molecular Medicine
MaxCyte
Mayo Clinic
MD Anderson Cancer Center
Medical College of Wisconsin
MedImmune
Medisix Therapeutics
MediTrust Health
Memorial Sloan Kettering Cancer Center
Merck
Mie University Hospital
Miltenyi Biomedicine
Miltenyi Biotec
Minerva Biotechnologies
Mink Therapeutics
Moderna
MolMed (acquired by AGC Biologics)
Mustang Bio
Nanfang Hospital of Southern Medical University
Nanjing Bioheng Biotech
Nanjing Children's Hospital
NantKwest
Nantong University
National Cancer Center Research Institute Japan
National Cancer Institute
National Heart, Lung and Blood Institute
National Institutes of Health (NIH)
National Institutes of Health Clinical Center
National Taiwan University Hospital
National University Hospital, Singapore
Navy General Hospital
NeoStem
Ningbo Cancer Hospital
NIPRO
Nkarta
Noile-Immune Biotech
Notch Therapeutics
Novartis
Novartis Venture Fund
nSAGE
NSF Engineering Research Center for Cell Manufacturing Technologies
Oncodesign Biotechnology
Oncora Medical
OncoTracker
Oncternal Therapeutics
Oncyte
ONK Therapeutics
oNKo-innate
ONO Pharmaceutical
Opus Bio
OrbiMed Advisors
Ospedale Pediatrico Bambino Gesù (OPBG)
Otsuka Pharmaceutical
Ottawa Hospital Research Institute
Outpace Bio
Overland Pharmaceuticals
Oxford Biomedica
Oxford Biotherapeutics
Oxford MEStar
panCELLa
Parker Institute for Cancer Immunotherapy
Pediatric Brain Tumor Consortium
Peking Union Medical College Hospital
Peking University People's Hospital
Peking University Shenzhen Hospital
Peking University Third Hospital
PeproMene Bio
PersonGen BioTherapeutics
Peter MacCallum Cancer Centre
Pfenex
Pfizer
PHARMALOG Institut für klinische Forschung
PhoreMost
Pieris Pharmaceuticals
Pierre Fabre
Pinze Lifetechnology
PLA General Hospital
Porton Biologics
Poseida Therapeutics
Precigen
Precision BioSciences
Pregenen
ProMab Biotechnologies
Protheragen
Qilu Hospital of Shandong University
RA Capital Management
Redmile Group
RedoxTherapeis
Refuge Biotechnologies
Regeneron Pharmaceutical
RenJi Hospital
resTORbio
Rockland Immunochemicals
Roger Williams Medical Center
Rosewell Park Comprehensive Cancer Center
Royal Adelaide Hospital Cancer Centre
Ruijin Hospital
Sabz Biomedicals
Sana Biotechnology
Sangamo Therapeutics
Sanofi
Scotia Biologics
Seattle Children’s Research Institute
Seattle Children's Hospital
Seattle Children's Research Institute
Second Affiliated Hospital of Guangzhou Medical University
Second Affiliated Hospital of Nanchang University
Second Affiliated Hospital of Suzhou University
Second Affiliated Hospital of Xi'an Jiaotong University
Second Military Medical University
Second Xiangya Hospital of Central South University
Servier
Shangai Cancer Institute
Shanghai Biomed-Union Biotechnology
Shanghai Bioray Laboratory
Shanghai Cell Therapy Group
Shanghai Changzheng Hospital
Shanghai Chest Hospital
Shanghai Children's Medical Center
Shanghai East Hospital
Shanghai GeneChem
Shanghai General Hospital
Shanghai International Medical Center
Shanghai Jiao Tong University School of Medicine
Shanghai Longyao Biotechnology
Shanghai Ming Ju Biotechnology
Shanghai OriginCell Therapeutics
Shanghai PerHum Therapeutics
Shanghai Pharmaceuticals
Shanghai Public Health Clinical Center
Shanghai Simnova Biotechnology
Shanghai Tong Ren Hospital
Shanghai Tongji Hospital
Shanghai Ultra-T Immune Therapeutics
Shanghai Unicar-Therapy Bio-medicine Technology
Shanghai Zhongshan Hospital
Shanxi Province Cancer Hospital
Shariati Hospital
Sheba Medical Center
Shenzhen Binde Biotechnology
Shenzhen BinDeBio
Shenzhen Children's Hospital
Shenzhen Geno-Immune Medical Institute
Shenzhen Hospital of Southern Medical University
Shenzhen Institute for Innovation and Translational Medicine
Shenzhen Second People's Hospital
Shenzhen University
ShiJiaZhuang Zhongxi Children Hospital
Shoreline Biosciences
Sichuan Kelun-Biotech Biopharmaceutical
Sichuan University
Simcere Pharmaceutical
Sinobioway Cell Therapy
Sistema and Russian Direct Investment Fund
Sorrento Therapeutics
Southern Medical University
Southwest Hospital
SpringWorks Therapeutics
St. Baldrick's Foundation
St. Jude Children's Research Hospital
Stage Cell Therapeutics
Stand Up To Cancer
Stanford University
Stony Brook University
Sun Yat-Sen University
Syncopation Life Sciences
Takara Bio
Takeda Pharmaceutical
TC BioPharm
TCRCure Biopharma
T-Curx
Tehran University of Medical Sciences
Tel Aviv Sourasky Medical Center
Temasek
Teneobio
Terumo BCT
Tessa Therapeutics
Texas Children's Hospital
The Affiliated Hospital Of Guizhou Medical University
The Affiliated Hospital of Xuzhou Medical University
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
The Beijing Pregene Science and Technology
The Children's Mercy Hospital
The Faris Foundation
The First Affiliated Hospital of Anhui Medical University
The First Affiliated Hospital of Dalian Medical University
The First Affiliated Hospital of Guangdong Pharmaceutical University
The First Affiliated Hospital of Kunming Medical College
The First Affiliated Hospital of Nanchang University
The First Affiliated Hospital of Nanjing Medical University
The First Affiliated Hospital of Soochow University
The First Affiliated Hospital of University of Science and Technology of China
The First Affiliated Hospital of Zhejiang University
The First Affiliated Hospital of Zhengzhou University
The First Affiliated Hospital with Nanjing Medical University
The First People's Hospital of Changzhou
The First People's Hospital of Hefei
The First People's Hospital of Yuhang District
The First People's Hospital of Yunnan
The Fourth Hospital of Hebei Medical University
The General Hospital of Western Theater Command
The Ohio State University
The Pregene (ShenZhen) Biotechnology
The Second Affiliated Hospital of Chongqing Medical University
The Second Affiliated Hospital of Hainan Medical University
The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine
The Second Hospital of Anhui Medical University
The Second Hospital of Hebei Medical University
The Second Hospital of Nanjing Medical University
The Seventh Affilliated Hospital
The Sixth Affiliated Hospital of Wenzhou Medical University
The Third People's Hospital of Kunshan
The Wistar Institute
ThermoFisher Scientific
Tianjin Medical University
Tianjin Medical University General Hospital
Tianjin Mycure Medical Technology
Ticaros
Timmune Biotech
Tiziana Life Sciences
Tmunity Therapeutics
Tongji Hospital
Tongji University
TrakCel
Transgene
Transposagen Biopharmaceuticals
TriArm Therapeutics
Trinity College Dublin
Tri-Service General Hospital
Triumph Over Kid Cancer Foundation
Tsinghua University
Twist Bioscience
TxCell
Ucello Therapeutics
UCL Business
UNC Lineberger Comprehensive Cancer Center
Union Stem Cell & Gene Engineering
United States Department of Defense
University College London
University Health Network
University of Alberta
University of Birmingham
University of California
University of Colorado
University of Milano-Bicocca
University of Minnesota
University of Munich
University of North Carolina
University of Pennsylvania
University of South Australia
University of Southern California
University of Texas
University of Washington
University of Washington and Seattle Cancer Care Alliance
University of Washington Cancer Consortium
University of Zurich
Uppsala University
USHEALTH
UTC Therapeutics
UWELL Biopharma
V Foundation
VCN Biosciences
venBio
Versant Ventures
Vineti
ViroMed
Vitruvian Networks
Vivo Capital
Washington University
Weill Cornell Medical College
Weill Medical College of Cornell University
Wellington Zhaotai Therapies
West China Hospital
West China Hospital of Sichuan University
Wugen
Wuhan Bio-Raid Biotechnology
Wuhan Sian Medical Technology
Wuhan Union Hospital
WuXi AppTec
X-Body
Xi'An Yufan Biotechnology
Xiangya Hospital of Central South University
Xiangyang Central Hospital
Xijing Hospital
Xinhua Hospital
Xinqiao Hospital
Xuanwu Hospital
Xuzhou Medical University
Yake Biotechnology
Yamaguchi University
Yan'an Affiliated Hospital of Kunming Medical University
Yunnan Cancer Hospital
Zhejiang Provincial People's Hospital
Zhejiang Qixin Biotech
Zhejiang University
Zhujiang Hospital

Source 1: https://www.cancer.org/research/cancer-facts-statistics/global.html
Source 2: https://www.nature.com/articles/s41587-022-01212-6

PRICING DETAILS

Single-User License USD 4,799

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

One Location Site License USD 6,999

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

Department License USD 10,599

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

Enterprise License USD 17,999

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com

CAR T Cell Therapy Market

CAR T Cell Therapy Market (4th Edition) by Target Indications, Target Antigens (CD19, BCMA, CD19 / CD22, EGFR, NY-ESO-1 and Others), Key Players and Key Geographies: Industry Trends and Global Forecasts, 2022-2035

CAR T Cell Therapy Market Overview

Key Market Insights

Pipeline Analysis: 600+ CAR T Cell Therapy Programs in Clinical Trials

CAR T Companies Analysis: Collaborations, Funding, Patents and More

Target Indication Analysis: Acute Lymphoblastic Leukemia, B-Cell Lymphoma and Multiple Myeloma to Drive CAR T Cell Therapy Market Growth

Regional Analysis: North America Holds the Largest Share of the Current CAR T Cell Therapy Market

Market Forces Analysis: Therapy Price and Manufacturing Challenges Likely to Slow Down the CAR T Therapy Market Growth

Recent Developments in CAR T Therapy Market

Scope of the Report

Frequently Asked Questions

Question 1: What is CAR T cell therapy?

Question 2: How many CAR-T therapies are on the market?

Question 3: What is the market size for CAR T cell therapy?

Question 4: What is the global CAR T cell therapy market growth?

Question 5: Who are the largest CAR T cell therapy companies?

Question 6: How many clinical trials are running for CAR-T therapies?

Question 7: What kind of partnership models are commonly adopted by players in CAR-T industry?

Question 8: How much funding has been raised in the CAR T-cell therapy market?

Question 9: How is the intellectual property landscape for global CAR T-cell therapy likely to evolve in the foreseen future?

Question 10: Who are the key CAR T cell therapy CMOs?

Question 11: What are the key promotional strategies used by CAR T cell therapy companies having marketed products?

Question 12: What is the outlook for CAR T therapy?

Table Of Contents

List Of Figures

List Of Tables

List Of Companies

Single-User License USD 4,799

One Location Site License USD 6,999

Department License USD 10,599

Enterprise License USD 17,999

YOU MAY ALSO LIKE

The Future Of Healthcare: Wearable Injectors Unveiled

Cannabis Testing / Hemp Testing: Unlocking the Future Opportunities in Healthcare

Market Insights Reports

Indication Specific Reports

CAR T Cell Therapy Market

CAR T Cell Therapy Market (4th Edition) by Target Indications, Target Antigens (CD19, BCMA, CD19 / CD22, EGFR, NY-ESO-1 and Others), Key Players and Key Geographies: Industry Trends and Global Forecasts, 2022-2035

CAR T Cell Therapy Market Overview

Key Market Insights

Pipeline Analysis: 600+ CAR T Cell Therapy Programs in Clinical Trials

CAR T Companies Analysis: Collaborations, Funding, Patents and More

Target Indication Analysis: Acute Lymphoblastic Leukemia, B-Cell Lymphoma and Multiple Myeloma to Drive CAR T Cell Therapy Market Growth

Regional Analysis: North America Holds the Largest Share of the Current CAR T Cell Therapy Market

Market Forces Analysis: Therapy Price and Manufacturing Challenges Likely to Slow Down the CAR T Therapy Market Growth

Recent Developments in CAR T Therapy Market

Scope of the Report

Frequently Asked Questions

Question 1: What is CAR T cell therapy?

Question 2: How many CAR-T therapies are on the market?

Question 3: What is the market size for CAR T cell therapy?

Question 4: What is the global CAR T cell therapy market growth?

Question 5: Who are the largest CAR T cell therapy companies?

Question 6: How many clinical trials are running for CAR-T therapies?

Question 7: What kind of partnership models are commonly adopted by players in CAR-T industry?

Question 8: How much funding has been raised in the CAR T-cell therapy market?

Question 9: How is the intellectual property landscape for global CAR T-cell therapy likely to evolve in the foreseen future?

Question 10: Who are the key CAR T cell therapy CMOs?

Question 11: What are the key promotional strategies used by CAR T cell therapy companies having marketed products?

Question 12: What is the outlook for CAR T therapy?

Table Of Contents

List Of Figures

List Of Tables

List Of Companies

Single-User License USD 4,799

One Location Site License USD 6,999

Department License USD 10,599

Enterprise License USD 17,999

YOU MAY ALSO LIKE

Antibody Discovery Market

Allogeneic Cell Therapy Market

ADC Technology Market

The Future Of Healthcare: Wearable Injectors Unveiled

Cannabis Testing / Hemp Testing: Unlocking the Future Opportunities in Healthcare